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UN GHSAlternative test methods often use prediction models (PMs) for converting endpoint measurements into predic-
tions. Two PMs are used for the skin corrosion tests (SCTs) of the OECD Test Guideline No. 431 (TG 431). One is
speciﬁc to EpiSkin™ test method, whereas EpiDerm™, SkinEthic™ RHE and epiCS® share a common PM. These
methods are based on reconstructed human epidermis models wherein cell viability values are measured. Their
PMs allow translating those values into sub-categories of corrosive chemicals, Category 1A (Cat1A) and a combi-
nation of Categories 1B/1C (Cat1BC), and identifying non-corrosive (NC) chemicals. EpiSkin™'s PM already
results in sufﬁciently accurate predictions. The common PM of the three others accurately identiﬁes all corrosive
chemicals but, for sub-categorization, an important fraction of Cat1BC chemicals (40–50%) is over-predicted as
Cat1A. This paper presents a post-hoc analysis of validation data on a set of n = 80 chemicals. It investigates:
why this common PM causes these over-predictions and how two novel PMs that we developed (PMvar1 and
PMvar2) improve the predictive capacity of these methods. PMvar1 is based on a two-step approach; PMvar2
is based on a single composite indicator of cell viability. Both showed a greater capacity to predict Cat1BC,
while Cat1A correct predictions remaining at least at the same level of EpiSkin™. We suggest revising TG 431,
to include the novel PMs in view of improving the predictive capacity of its SCTs.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).-category of corrosive chemical
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1.1. RhE testmethods and their regulatory importance for the skin corrosion
endpoint
ReconstructedhumanEpidermis (RhE)models are used in in vitro test
methods for dermal acute toxicity (OECD, 2013b; OECD, 2014b). These
models are constructed with human-derived epidermal keratinocytes
and constitute a three dimensional structure reproducing the typical
multi-layer cell organization of the epidermis.
They are used for different applications. One of them is the skin corro-
sion test (SCT) for the assessment of potential skin corrosive chemicals as
described in the OECD Test Guideline (TG) No. 431 (OECD, 2014b). Skin
corrosion is deﬁned as irreversible damage to the skin following the ap-
plication of a test chemical (UN, 2013). Clinically, necrosis is observed
through the epidermis and into the dermis following the exposure to the
chemical.
The assessment and classiﬁcation of chemicals by the GHS United Na-
tions (UN) Global Harmonized System of classiﬁcation and labeling of
chemicals (GHS) (UN, 2013) follow a tiered approach as described in itsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
UN GHS sub-categories of corrosive chemicals.
Category 1: corrosive
(applies to authorities not using sub-categories)
Corrosive sub-categories
(only applies to some authorities)
Corrosive in ≥1 of 3 animals
Exposure Observation
Corrosive 1A ≤3 min 1 h
1B ≥3 min and b1 h 14 days
1C ≥1 and ≤4 h 14 days
2056 B. Desprez et al. / Toxicology in Vitro 29 (2015) 2055–2080Annex 3. It considers human data, animal data and in vitro data. The UN
GHS labels as Category 1 chemicals that are classiﬁed as corrosive for
the skin. These chemicals can be further sub-categorized (Categories 1A,
1B and 1C) depending on in vivo effects observed both during the expo-
sure time and later during the observation period as presented in Table 1.
The identiﬁcation of corrosive chemicals falls under several regula-
tions. The UN GHS serves as a basis for the European Union System of
Classiﬁcation of Chemicals, implemented in the EUClassiﬁcation, Labeling
and Packaging Regulation (EU CLP). It is also important for transport
regulation of chemicals based on the UN Transport of Dangerous Goods
Regulation (TDG) (UN, 2011). The assessment of the skin corrosion po-
tential of chemicals is also mandatory under the REACH regulation in
Europe (EC, 2001; EC, 2006; EC, 2008). Chemicals labeled as corrosive
will lead to taking similar protectionmeasures, for human health, regard-
less of its corrosive sub-category. However sub-categorization remains
essential with regard to transportation safety measures, in order to com-
plywith the EU CLP that requires both categorization and sub-categoriza-
tion (UN, 2011; UN 2013). Transportmeasures to be takenwith regard to
Cat1A aremuchmore costly and stringent than those for Cat1B andCat1C.
Sub-categorizationwill also be of importance for any other (future) legis-
lation that would be affected by the need to make these distinctions.
Therefore, in vitro test methods that are sufﬁciently capable to
make sub-categorization predictions, will be beneﬁcial to (i) avoid un-
necessary in vivo testing for sub-categorizing corrosive chemicals, (ii) re-
duce the unnecessary costs for the transport of Cat1B or Cat1C chemicals.
Importantly, the evaluation of skin corrosion (and irritation) using
alternativemethods (such as RhE) needs to be done through integrative
approaches that allow for the consideration of complementary informa-
tion (e.g., physicochemical properties, QSARs). An integrated approach
on testing and assessment (IATA) (OECD, 2014a) is already accepted
at the international level, where the RhE test methods play a key role.
This IATA used the Integrated Testing Strategy (ITS) developed in the
context of the REACH guidance (latest update ECHA, 2014). It is expect-
ed to lead to a revision of the “Testing and Evaluation Strategy” includ-
ing the OECD TG 404 (OECD, 2002) in view of reﬂecting the scientiﬁc
and technical progress that is presented in the IATA.Table 2
Prediction types for categorization and sub-categorization of corrosive chemicals in OECD
TG 431.
Test method
(using OECD TG 431)
Classiﬁcation of corrosive
chemicals
Predictions
performed
EpiSkin™, EpiDerm™,
SkinEthic™ RHE, epiCS®
Categorization Corr. vs. Non-Corr.
(Partial) Sub-categorization 1A vs. 1BC vs. Non-Corr.1.2. Background of the OECD TG 431: binary categorization and partial
sub-categorization of corrosive chemicals with high over-prediction rates
of Cat 1BC observed in 3 out of 4 methods
The initial version of the OECD TGNo. 431 in 2004 allowed binary cat-
egorization of corrosive (Category 1) versus non-corrosive (NC)
chemicals. This binary categorization is still presented in the current ver-
sion of TG 431. Additionally this guideline was revised in 2012–2014 to
allow for sub-categorization of corrosive chemicals. During this revision,
the OECD expert group decided in September 2012 to consider predic-
tions that separate Cat1A from a combination of Cat1B/Cat1C. This was
done for two reasons: (i) it was deemed that the ability of RhE methods
for discriminating between category 1B and category 1C was not sufﬁ-
ciently demonstrated and (ii) the most important differences in terms
of cost/safety measures exist between Cat1A and Cat1B. In this regard,
in 2013 and 2014 the updated versions of TG 431 present the sub-
categorization abilities of RhE test methods by considering predictions
type ‘Cat1A versus Cat1BC versus non-corrosive’, where “Cat1BC” repre-
sents this combination of Cat1B and Cat1C (OECD, 2013a; OECD, 2014b).The OECD Test Guideline No. 431, in its current version, includes four
skin corrosion test methods (SCTs): EpiSkin™, EpiDerm™, SkinEthic™
RHEandepiCS® (Table 2). In 2004 it includedoriginally twovalidated ref-
erencemethods (VRMs), based on EpiSkin™ and EpiDerm™ RhEs for the
binary categorization (corrosives versus non-corrosives). It has been up-
dated in July 2013 to include two additional test methods, SkinEthic™
RHE and epiCS® SCTs on the basis of a performance standard-based vali-
dation procedure. In that version of TG 431 it was stated that EpiDerm™,
EpiSkin™ and SkinEthic™ RHE SCTs were additionally able to partially
sub-categorize within the corrosive category—with distinct abilities. The
guideline was then revised in July 2014 to include also epiCS® abilities
to partially sub-categorize corrosive chemicals (Table 2).
TG 431 stipulates that predictions obtained with EpiSkin™ SCT can be
used directly as they are, i.e., relying directly to the EpiSkin™ sub-
categorization predictions (Cat1A and Cat1BC) established by its predic-
tion model. In contrast, for EpiDerm™, SkinEthic™ RHE and epiCS®, the
guideline states that chemicals forwhich the outcome is Cat1BC can bedi-
rectly considered as Cat1BC whereas those for which the outcome is
Cat1A should either be labeled as Cat1 (corrosive) or should undergo fur-
ther testing to conﬁrm the result of the sub-categorization. This latter rec-
ommendation is related to high over-prediction rates for Cat1BC (40–50%
of those chemicals over-predicted as Cat1A)when using the common PM
of these three test methods (OECD, 2013c; OECD, 2013a; OECD, 2014b).
1.3. Scope of the paper: possibilities for better sub-categorizing in OECD TG
431
The original common PMof EpiDerm™, SkinEthic™ RHE and epiCS®
was initially developed only for the binary categorization (predictions
corrosive versus non-corrosive chemicals). In the context of the revision
of TG 431 described above, this common PM was adapted for sub-
categorization using a cutoff of 50% cell viability value at 3 min. How-
ever it has never been systematically investigated to which extent
these adaptations were appropriate for the three SCTs using this com-
mon PM and whether other PMs would provide more accurate predic-
tions. This paper does this investigation: it examines (i) the current
PMs for sub-categorization & causes of over-predictions, and (ii) pro-
poses two new PMs for EpiDerm™, SkinEthic™ RHE and epiCS® in
order to improve their predictions under the OECD TG 431. Predictions
from EpiSkin™ SCT were used for comparison purposes. That means
that the corresponding rates served as target values for the three
other tests for which the investigation is performed (see Section 2.2).
2. Material and method
2.1. Material
The material is composed of data obtained from the four RhE
methods, EpiSkin™, EpiDerm™, SkinEthic™ RHE, and epiCS® after
Table 3
Contingency table for evaluating the concordance of in vitro results with in vivo classiﬁcation.
RhE test method considered, 80 chemicals tested in 2 or 3 independent runs, with original PM or PMvar1 or PMvar2
In vivo In vitro predictions
1A 1BC NC Total
1A Correct predictions for 1A
Number a→ (a/n1) × 100
1A under-predicted as 1BC
Number b→ (b/n1) × 100
1A under-predicted as NC
Number c→ (c/n1) × 100
n1 = a + b + c
1BC 1BC over-predicted as 1A
Number d→ (d/n2) × 100
Correct predictions for 1BC
Number e→ (e/n2) × 100
1BC under-predicted as NC
Number f→ (f/n2) × 100
n2 = d + e + f
NC NC over-predicted as 1A
Number g→ (g/n3) × 100
NC over-predicted as 1BC
Number h→ (h/n3) × 100
Correct predictions for NC
Number i→ (i/n3) × 100
n3 = g + h + i
Total a + d + g b + e + h c + f + i n1 + n2 + n3 = N
Overall accuracy = ((a + e + i) / N) × 100
Table 4
Predictionsmodels of EpiDerm™, SkinEthic™ RHE, epiCS® and EpiSkin™ used inOECDTG
431 (revised versions of 2013 and 2014).
Test method Prediction model Prediction
EpiDerm™SCT,
SkinEthic™RHE,
epiCS®
v3 b 50% Category 1A
{v3 ≥ 50%} AND {v60 b 15%} Category 1BC
{v3 ≥ 50%} AND {v60 ≥ 15%} Non-corrosive
EpiSkin™ {v3 b 35%} AND {Any value of v60, v240 min} Category 1A
{v3 ≥ 35%} AND {v60 b 35%} AND
{Any Value of v240} OR {v3 ≥ 35%}
AND {v60 ≥ 35%} AND {v240 b 35%}
Category 1BC
All cell viabilities ≥35% Non-corrosive
2057B. Desprez et al. / Toxicology in Vitro 29 (2015) 2055–2080obtaining authorization from the test methods' developers to use them.
These data come from their respective validation studies (Alépée et al.,
2014a; Alépée et al., 2014b; Barratt et al., 1998; Hoffmann et al., 2005;
Kandárová et al., 2006; Liebsch et al., 2000; Kandárová et al., 2014 and
Tornier et al., 2010), implementing their respective protocols with re-
gard to the evaluation of skin corrosive chemicals. For the purpose
of including in TG 431 the sub-categorization abilities of these four
methods, additional data were generated. Results for EpiDerm™
and epiCS® have never been published and we report them here
on the basis of their current PM, PMvar1 and PMvar2. Results for
EpiSkin™ and SkinEthic™RHE were reported recently on the basis
of their current PM only (Alépée et al., 2014a; Alépée et al., 2014b)
and we report here those for SkinEthic™ on the basis of PMvar1
and PMvar2. For all methods, we performed a post-hoc analysis on
these data (see Section 2.2).
For eachmethod, the principle of the test is the same. Brieﬂy, the test
chemical is topically applied to the RhE test tissues. The output is the
measurement of the optical density (OD) at different time points (3
and 60 min for all, and also 240 min for EpiSkin™) through the “MTT
assay”. The vital dye MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide, Thiazolyl blue tetrazolium bromide; CAS number
298-93-1] is enzymatically reduced into blue formazan that allows
quantitative measurements of its OD. The OD serves to derive relative
cell viability values. The value of 100% cell viability is set to the ODmea-
sured for the negative control. For each of the test chemicals, the relative
cell viability is then obtained from their OD in proportion to the one of
the negative control. For colored chemicals and/or for direct MTT-
reducer chemicals raw OD has to be corrected prior to deriving the
ﬁnal cell viability. After measurements of the OD and linear conversion
into cell viability values, the results provide cell viability at 3 and 60min
for EpiDerm™, SkinEthic™RHE and epiCS®, and additionally at 240min
for EpiSkin™. These values serve to the prediction models. The set ofTable 5
Prediction model variation 1 (PMvar1), based on a two-step approach.
Step1: Corr. vs. Non-Corr. {v3 b 50} OR {v3 ≥ 50 AND v60 b 15}→ Corr.
Step2: Cat. 1A vs. Cat. 1B/1C v3 b x→ Cat. 1Adata considers 80 chemicals (Table 9) that the four test methods tested
in common. Those chemicals have been tested over 3 runs by EpiSkin™,
EpiDerm™ and SkinEthic™ RHE, and over 2 runs by epiCS®. They had
been previously classiﬁed using the in vivo test (OECD TG 404) and
were thus included in our analysis into three ‘in vivo groups’ complying
with OECD TG 431: in vivo non-corrosive (NC); in vivo Cat1BC (1BC);
and in vivo Cat1A (1A), following what has been agreed by the OECD
expert group (see Section 1.2).
2.2. Data analysis
2.2.1. Statistical analysis performed
The statistical analysis, including contingency tables, boxplots and
ROC curves, was performed on Stata®12 (SE version). Boxplots show
median (line within box), 25th percentile (lower hinge) and its lower
adjacent value (lower adjacent line), 75th percentile (upper hinge) and
its upper adjacent value (upper adjacent line), and outside values (dots).
Results from EpiSkin™ SCT were used as target values in this study
for three reasons: (i) its PM was developed from the beginning for
sub-categorization (Fentem et al., 1998), (ii) the OECD TG 431 states
that its predictions resulting in Cat1A and Cat1BC can be accepted with-
out need of further testing, and (iii) its over-prediction rates of Cat1BC
(over-predicted as Cat1A) reaches a quite low level of 21%.
The statistical analysis aims to compare the predictions obtained with
the current PMs to those that are obtained with the two novel PMs that
we developed, PMvar1 and PMvar2. In order to accurately provide this
‘before/after’ picture, the analysis complies with the way of calculations
underlying the current version of OECD TG 431 and as laid out in the
annexed performance standards (OECD, 2013c; OECD, 2013a). That
means that calculations of the capacity of the testmethods to predict sub-
categories were based on all runs generated. That implies that informa-
tion generated on run level was not further processed to arrive at one
single prediction per test chemical (for instance by taking the median or
mean of cell viabilities or themode of runpredictions). It is acknowledged
that this approach seems to increase the sample size by effectively tripling
(or doubling depending on the data sets associated with the test
methods) the number of data points as compared to the number of
chemicals tested. This will lead to narrower Conﬁdence Intervals.
However, for the purposes of this paper, in order to be able to compare
the performance of the novel prediction models with those included in
the current version of TG 431, the exact same way of calculating
sensitivity and speciﬁcity values had to be used, as this had been done
in the analyses performed in 2012 which underlie the present version
of TG 431. Therefore, the data matrices analyzed in this paper are as
follows: for EpiDerm™, EpiSkin™ and SkinEthic™ RHE each of the 80v3 ≥ 50 AND v60 ≥ 15→ Non-Corr. v3 ≥ 50 AND v60 ≥15→ Non-Corr.
v3 ≥ x→ Cat. 1B/1C –
Table 6
Prediction model variation 2 (PMvar2), based on a composite cell indicator ‘vﬁn’.
Establishment of composite indicator 'vfin' Theoretical range of 
values for ‘vfin’
Criteria Prediction
v3 < 50 vfin = v3 [0; 50[ vfin < y Cat1A
v3 ≥ 50 AND v60 <15 vfin = v3 + v60 [50; 115[ y ≤ vfin < z Cat1BC
v3 ≥ 50 AND v60 ≥ 15 vfin = (2 × v3) + v60 [115; 300[ vfin ≥ z Non-corrosive
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predictions. For epiCS® each chemical was tested in 2 independent runs
except chemical No. 58 (glycol bromoacetate (85%)) tested in 1 run
only. Thus, the epiCS® data matrix consists of 159 predictions (79
chemicals tested twice plus 1 chemical tested once). The run data are pre-
sented in Table 9.
For the purpose of the analysis, 3 × 3 contingency tables such as
Table 3 have been used. These tables were obtained on the basis of the
original PM as included in TG 431 and the two novel PMs. This allows
evaluating, for each PM used, the concordance of the in vitro sub-
categorization with the in vivo sub-categorization. Results obtained in
the contingency tables present the number of predictions over all runs
for each method on the set of 80 chemicals. For each in vivo sub-
category number and percentages of correct and possible under- and/
or over-predictions are calculated (see Table 3). The overall accuracy
has been also calculated. The contingency table obtained for EpiSkin™,
using its current PM, serves as a reference for comparison to the other
three methods for which the novel PMs are tested. Therefore for
EpiDerm™, SkinEthic™ RHE and epiCS® the contingency tables
were obtained according to 3 modalities, using their common cur-
rent PM and the two new variations, PMvar1 and PMvar2.
Results obtained for PMvar1 and PMvar2 are compared to those
obtained with the original common PM. We focus on Cat1BC where
over-predictions are encountered for the three methods with the origi-
nal PM. This allows assessing whether the changes of PMs resulted in
signiﬁcant improvements. In the end, Receiver Operating Characteristic
(ROC) curves were also obtained thanks to PMvar2 and allow compar-
ing the four methods performances for identifying each of the three
sub-categories of TG 431.
For both PMvar1 and PMvar2 several cutoff values have been envis-
aged. For each of these possible cutoffs, we obtained 3 × 3 contingency
tables with calculations of correct prediction rates, over- and under-
prediction rates and overall accuracy. These tables are reported with 2
possible cutoffs according to two different goals. The ﬁrst one maxi-
mizes the correct predictions for Cat1BC. The second onemaximizes si-
multaneously correct predictions of Cat1BC and Cat1A to obtain a
correct prediction value of Cat1A at least equal to EpiSkin™ SCT.2.2.2. Original prediction models of the four RhE methods
EpiDerm™, SkinEthic™ RHE and epiCS® SCTs use the common pre-
dictionmodel based on cutoff values of cell viability at 3 (v3) and 60min
(v60). EpiSkin™ uses a different prediction model with cutoff values of
cell viability at 3 (v3), 60 (v60) and 240min (v240). Original prediction
models included in the revised versions of 2013 and 2014 of OECD TG
431 are presented in Table 4.Table 7
EpiDerm™, SkinEthic™ RHE and epiCS®, obtaining of ROC curves based on PMvar2.
EpiDerm™, SkinEthic™ RHE
and epiCS®
vﬁn composite indicator (for prediction Cat1A
versus others; Non-Corr. versus others)
v3 b 50 vﬁn = v3
v3 ≥ 50 AND v60 b 15 vﬁn = v3 + v60
v3 ≥ 50 AND v60 ≥ 15 vﬁn = (2 × v3) + v60In the EpiDerm™, SkinEthic™ RHE and epiCS® SCTs, the cutoff
values for v3 and v60 are 50% and 15% respectively, and classiﬁcation
of chemicals are performed depending on the ranges of v3 and v60. In
the EpiSkin™ SCT v3, v60 and v240 have all a cutoff value of 35% and
combination of their possible ranges is different to classify chemicals
(Table 4).
2.2.3. The two novel prediction models, PMvar1 and PMvar2
These new prediction models are applied to EpiDerm™, SkinEthic™
RHE and epiCS®. Results from EpiSkin™ are considered here as target
values to be reached by EpiDerm™, SkinEthic™ RHE and epiCS® thanks
to the implementation of the new prediction models, as explained in
Section 2.2.
2.2.4. New prediction model variation 1 (PMvar1)
The ﬁrst variation (PMvar1) consists of a two-step approach where
corrosive and non-corrosive chemicals are classiﬁed based on the orig-
inally validated PM and in the second step, the group of corrosive
chemicals identiﬁed undergoes sub-categorization based on different
values of cell viabilities obtained at 3 min (Table 5):
Step1 Using the current prediction model to identify corrosive and
non-corrosive chemicals: chemicals for which v3 ≥ 50 &
v60 ≥ 15 are considered as non-corrosive, whereas all other com-
binations of v3 and v60 are considered as corrosive;
Step2 Chemicals identiﬁed as corrosive under step 1 are sub-
categorized using a cutoff x of cell viability at 3 min (v3),
i.e., predictions are Cat1A for values of v3 below x, and Cat1BC
for values of v3 equal or above x.
The value of the x cutoff was determined for each of the RhEs
separately by the custom-made program developed for this pur-
pose. Boxplot graphs of the cell viabilities over the in vivo sub-
categories are presented to demonstrate which cutoff is optimal
for discriminating between Cat1A and Cat1BC.
2.2.5. New prediction model variation 2 (PMvar2)
PMvar2 linearly combines v3 and v60 to establish a composite cell
viability indicator, noted vﬁn, that stands for “ﬁnal cell viability”, and
that serves afterwards as a basis for providing predictions for sub-
categorization (Table 6). Combination of v3 and v60 to obtain vﬁn fol-
lows different modalities (Table 6). This vﬁn composite indicator of
cell viability aims to facilitate sub-category predictions on the basis of
one value instead of considering several ranges of cell viability valuesvalt composite indicator (for predictions
Cat1BC versus others)
Predicted Category
valt = 3 × (100− vﬁn) Cat1A
valt = vﬁn Cat1BC
valt = vﬁn Non-corrosive
Table 8
EpiSkin™, obtaining of ROC curves derived from PMvar2.
EpiSkin™ vﬁn composite indicator (for predictions Cat1A
versus others; or Non-Corr. versus others)
valt composite indicator (for predictions
Cat1BC versus others)
Predicted category
v3 b 35 vﬁn = v3 valt = 4 × (100− vﬁn) Cat1A
v3 ≥ 35 AND v60 b 35 vﬁn = v3 + v60 valt = vﬁn Cat1BC
v3 ≥ 35 AND v60 ≥ 35 AND v240 b 35 vﬁn = v3 + v60 + v240 valt = vﬁn
v3 ≥ 35 AND v60 ≥ 35 AND v240 ≥ 35 vﬁn = ((4 × v3) + v60 + v240) valt = vﬁn Non-corrosive
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predictions as well as overall accuracy of the method.
This PM assumes that, theoretically, cell viability valueswould be in-
cluded in a range of 0 to 100%. However some values of v3 are above
100% in the dataset and therefore, although PMvar2 (Table 6) would
be the best possible case, some values of vﬁn might be still overlapping
in sub-categories. Nonetheless such overlaps between sub-categories of
chemicals would be reduced when compared to original prediction
model. As the intervals of vﬁn overlap in a lower extent, discriminating
between the three sub-categories may result in a greater overall
accuracy.
On this theoretical basis, PMvar2was then developed for EpiDerm™,
SkinEthic™ RHE and epiCS® using the composite cell viability
‘vﬁn’, thanks to the custom-made program and the boxplot graph
representing the distribution of vﬁn over the in vivo sub-categories.
Two cutoff values were thus derived from vﬁn distribution, y and z
respectively for discriminating Cat1A chemicals from Cat1BC and for dis-
criminating noncorrosive chemicals from all the others. This provides in
the end also a classiﬁcation type Cat1A versus Cat1BC versus non-
corrosive (Table 6).
2.2.6. Obtaining of ROC curves when PMvar2 is applied
Since PMvar2 is based on single cell viability composite indicator
‘vﬁn’, it allows obtaining of Receiver Operating Characteristic (ROC)
curves easily. In contrast, obtaining ROC curves on the basis of several
continuous variables v3, v60 (and v240) would require the use of logis-
tic modeling (Cleves et al., 2002). For prediction types ‘Cat1A versus
other categories’ or ‘Non-Corr. versus other categories’ vﬁn can be
used. For prediction types ‘Cat1BC versus other categories’ the range
of cell viability values of Cat1BC is between those of Cat1A and Non-
Corr. and renders the obtaining of ROC curvesmore delicate but still fea-
sible. For this latter case, the range of values for Cat1BC has to be differ-
ent from the two others (Cat1A and Non-Corr.) and not remain in
between. This is achieved by making the values of Cat1A fall under
those of Non-Corr. after a linear transformation. Therefore another com-
posite indicator ‘valt’ was developed on the basis of ‘vﬁn’ as outlined in
Table 7.
For the case of EpiSkin™ROC analysis also needs the development of
composite cell viability indicators vﬁn and valt, like for the three other
methods in PMvar2. However the development of these indicators has
been adapted to the speciﬁc PM of EpiSkin™ (Table 8). Similarly to
the other three test methods, for EpiSkin™ y and z values were chosen
to implement PMvar2 to EpiSkin™ and enable the ROC analysis. Results
of EpiSkin™ are presented in Table 9 with y = 40 and z = 380. ROC
analysis and its results are detailed in Section 4.3.1.
3. Results
3.1. Cell viabilities obtained with the four RhE methods
Table 9 provides for each test method and each of the 80 chemicals
used for the study the cell viability values at 3 and 60 min, as well the
values of the composite indicator vﬁn that are used in PMvar2 (see
Section 2.2). The results of in vitro sub-categorization are provided for
three cases: using the current PM (as included in OECD TG 431); using
PMvar1 (when taking the cutoff that gave best predictions, seeSection 3.3) and using PMvar2 (when taking the cutoff that gave best
predictions, see Section 3.4). According to UNGHS in vivo classiﬁcations
within the set of test chemicals are: for Cat1A n = 12 chemicals; for
Cat1BC n = 31 chemicals and for Non-Corr. n = 37 chemicals.
EpiDerm™ and SkinEthic™ RHE tested each of the 80 chemicals three
times (runs) and provided therefore 240 predictions; epiCS® tested 79
out of 80 chemicals twice and 1 once, provided therefore 159 predictions.
Cell viabilities presented are ﬁnal viabilities i.e., after correction for MTT-
reducing and/or colored chemicals. The composite indicator ‘vﬁn’ of cell
viability as described in the Data analysis section is also presented.
3.2. Analysis of the predictive ability of the original PMs
As shown in 3 × 3 contingency tables (Tables 10–13) the original
PMs in all four methods lead to high levels of correct prediction rates
for Cat 1A (83–91%) and Non-Corr. chemicals (72–88%). In EpiSkin™
the over-prediction rates of Cat1BC (over-predicted as 1A) is 21.5%. In
EpiDerm™, SkinEthic™ RHE, and epiCS®, that have a common PM,
this over-prediction rate of Cat1BC falls within 42–54% (depending on
the method).
These results constitute a veriﬁcation of what TG 431 states about
their sub-categorization abilities. Those are assessed in percentages of
the total number of predictions:
• For EpiSkin™ correct predictions rates for Cat1A, Cat1BC, and NC are
83.33%, 76.34%, and 79.28% (Table 10).
• For the three other methods the correct prediction rates for Cat1A are
close to 90% (86.11% to 91.67%), for Cat1BC slightly above or below
50% (from 46.24% to 58.06%) and for NC slightly above 70%, and there-
fore almost 50% of Cat1BC are over-predicted as Cat1A (Tables 11, 12
and 13).
Figs. 1, 2 and 3, present boxplot graphs for the distribution of cell vi-
ability values at 3 and 60 min in EpiDerm™, SkinEthic™ RHE and
epiCS®. In all 3 ﬁgures the cutoff of 50% for v3 and 15% for v60 is
represented.
For the EpiDerm™, SkinEthic™ RHE and epiCS, the cutoff of v60 =
15% seems appropriate to discriminate non-corrosive and corrosive (to-
gether 1A and 1BC) chemicals as a huge majority of non-corrosive
chemicals are above this cutoff, and a majority of Cat1A and Cat1BC
are below it. In contrast the cutoff of v3= 50% does not seem optimum.
For the three test methods, we observe that all Cat1A chemicals are
below the cutoff, but only almost half of the Cat1BC is above it. The
rest of Cat1BC are thus below this cutoff and will be over-predicted as
Cat1A. This explains the high over-prediction rates observed for the
three test methods regarding Cat1BC. Interestingly, all non-corrosive
chemicals are above this cutoff.
For EpiSkin™, the distribution of cell viability values shows that the
cutoff of 35% in its speciﬁc PM is appropriate in a majority of cases. That
means that for a majority of combinations of v3, v60 and v240 (in
EpiSkin™ PM) the three possible predictions (Cat1A, Cat1BC or Non-
Corr.) will be discriminated. For example, the boxplot graph (Fig. 4)
shows that a huge majority of Cat1A chemicals present cell viability
values below 35%, and a huge majority of Non-Corr. chemicals present
cell viability values over 35%. For Cat1BC, the PM requires that v3 ≥ 35
with at least either v60 or v240 b 35. The boxplot for Cat1BC chemicals
Table 9
List of tested chemicals, CASRN, in vivo classiﬁcation according to UNGHS, and corresponding cell viability values and in vitro classiﬁcations performed according to several PMs. 1A: category 1A; 1BC: combined category 1B/1C; NC: non-corrosive; L:
liquid; S: solid; V: viscous; green cells: correct predictions; red cells: over-predictions; blue cells: under-predictions.
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1 o–Methoxyphenol (guaiacol) 90–05–1 NC L 64.5 8.6 73.1 1BC 1BC 1BC 99.1 11.1 110.2 1BC 1BC 1BC 81.3 6.1 87.4 1BC 1BC 1BC
2 2,4–Xylidine (2,4–
dimethylaniline)
95–68–1 NC L 114.7 12.1 126.8 1BC 1BC NC 73 17.9 163.9 NC NC NC 92 5.1 97.1 1BC 1BC 1BC
3 Phenethyl bromide (2–
bromoethy benzene)
103–63–9 NC L 112.5 71.2 296.2 NC NC NC 72 22.2 166.2 NC NC NC 98.9 97.6 295.4 NC NC NC
4 Butyl carbamate 592–35–8 NC S 94.1 30.6 218.8 NC NC NC 84 27.8 195.8 NC NC NC 97.1 24 218.2 NC NC NC
5 L–Glutamic acid 
hydrochloride
138–15–8 NC S 98.9 50.7 248.5 NC NC NC 92.7 78 263.4 NC NC NC 102.8 71.4 277 NC NC NC
6 1–(o–Tolyl)biguanide 93–69–6 NC S 88.4 63.1 239.9 NC NC NC 84.7 79.8 249.2 NC NC NC 69.6 70.3 209.5 NC NC NC
7 Butyl glycolate (polysolvan) 7397–62–8 NC L 83.7 19.4 186.8 NC NC NC 93.2 23.7 210.1 NC NC NC 110.4 5.9 116.3 1BC 1BC NC
8 2–Hydroxyisobutyiric acid 594–61–6 NC S 97.4 9.5 106.9 1BC 1BC 1BC 92 7 99 1BC 1BC 1BC 90 10.6 100.6 1BC 1BC 1BC
9 Oxalic acid dihydrate 6153–56–6 NC S 86.6 6.3 92.9 1BC 1BC 1BC 91.6 6.4 98 1BC 1BC 1BC 100 4.2 104.2 1BC 1BC 1BC
10 Alpha–Ketoglutaric acid 328–50–7 NC S 90.9 4.6 95.5 1BC 1BC 1BC 68.7 12 80.7 1BC 1BC 1BC 105.7 6.5 112.2 1BC 1BC 1BC
11 Sulphamic acid 5329–14–6 NC S 93.7 6.9 100.6 1BC 1BC 1BC 81.7 7.4 89.1 1BC 1BC 1BC 85.2 8.9 94.1 1BC 1BC 1BC
12 Dodecanoic acid (lauric acid) 143–07–7 NC S 90.7 64.4 245.8 NC NC NC 94.9 93.4 283.2 NC NC NC 104.6 84.5 293.7 NC NC NC
13 Sodium lauryl sulphate (20%) 151–21–3 NC L 102.1 77.9 282.1 NC NC NC 101.2 108 310.4 NC NC NC 101.4 56.8 259.6 NC NC NC
14 Methyl trimethylacetate 598–98–1 NC L 99.6 27.6 226.8 NC NC NC 90.4 31 211.8 NC NC NC 103.1 16.3 222.5 NC NC NC
15 4–Amino–4H–1,2,4–triazole 584–13–4 NC S 105.7 88.2 299.6 NC NC NC 88.9 95.2 273 NC NC NC 102.8 110.8 316.4 NC NC NC
16 1,9–Decadiene 1647–16–1 NC L 97.6 102.8 298 NC NC NC 89.2 101.9 280.3 NC NC NC 104.6 114.8 324 NC NC NC
17 Sodium carbonate (50%) 497–19–8 NC L 104.5 46.6 255.6 NC NC NC 102.9 102.9 308.7 NC NC NC 99.6 86.7 285.9 NC NC NC
18 Benzylacetone (4–phenyl–2–
butanone)
2550–26–7 NC L 114.2 95.2 323.6 NC NC NC 89.5 131.1 310.1 NC NC NC 110.6 102.1 323.3 NC NC NC
19 Eugenol 97–53–0 NC L 113.4 28.3 255.1 NC NC NC 119.1 24.5 262.7 NC NC NC 104.2 –10.4 93.8 1BC 1BC 1BC
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20 Tetrachloroethylene 127–18–4 NC L 109.1 47.7 265.9 NC NC NC 105.1 66.7 276.9 NC NC NC 114.8 45.5 275.1 NC NC NC
21 Sodium undecylenate (33%) 3398–33–2 NC L 99.6 8.7 108.3 1BC 1BC 1BC 91.3 7.8 99.1 1BC 1BC 1BC 94.2 7 101.2 1BC 1BC 1BC
22 4–Amino–5–methoxy–2–
methylbenzensulphonic acid
6471–78–9 NC S 103.1 83 289.2 NC NC NC 95.9 109.2 301 NC NC NC 93.2 95.7 282.1 NC NC NC
23 Potassium hydroxide (5%) 1310–58–3 NC L 14.3 6.9 14.3 1A 1A 1A 23 8.2 23 1A 1A 1A 15.2 7.9 15.2 1A 1A 1A
24 3,3–Dithiopropionic acid 1119–62–6 NC S 89.2 91.2 269.6 NC NC NC 93.3 94.5 281.1 NC NC NC 88.6 94.4 271.6 NC NC NC
25 Isopropanol 67–63–0 NC L 86.8 77.9 251.5 NC NC NC 99.6 52.1 251.3 NC NC NC 92.3 83.8 268.4 NC NC NC
26 2–Phenylalcohol (2–Phenetyl 
ethanol)
60–12–8 NC L 89.4 5.4 94.8 1BC 1BC 1BC 90.9 5.9 96.8 1BC 1BC 1BC 98.7 –0.6 98.1 1BC 1BC 1BC
27 n–Butyl propionate 590–01–2 NC L 91.4 51.1 233.9 NC NC NC 91.9 62.9 246.7 NC NC NC 90.3 48.8 229.4 NC NC NC
28 Methyl palmitate 112–39–0 NC S 97.7 98.9 294.3 NC NC NC 85.6 84.7 255.9 NC NC NC 96.4 94.7 287.5 NC NC NC
29 Methyl laurate 111–82–0 NC L 96.3 90.6 283.2 NC NC NC 97.3 104.1 298.7 NC NC NC 105.1 100.1 310.3 NC NC NC
30 Sodium bicarbonate 144–55–8 NC S 90.8 90.2 271.8 NC NC NC 93.3 96.9 283.5 NC NC NC 102.2 94.1 298.5 NC NC NC
31 2–Bromobutane 78–76–2 NC L 82.2 14.6 96.8 1BC 1BC 1BC 90.2 23.3 203.7 NC NC NC 98.5 19.5 216.5 NC NC NC
32 4–(Methylthio)–benzaldehyde 3446–89–7 NC L 85.4 81.6 252.4 NC NC NC 94.8 86.3 275.9 NC NC NC 103.9 85.6 293.4 NC NC NC
33 2–Ethoxyethyl methacrylate 2370–63–0 NC L 84.1 56.8 225 NC NC NC 85.7 69.1 240.5 NC NC NC 96.5 60.5 253.5 NC NC NC
34 Cinnamaldehyde 14371–10–9 NC L 82.7 54.2 219.6 NC NC NC 86.6 60.6 233.8 NC NC NC 107.8 42.9 258.5 NC NC NC
35 4,4´–Methylene–bis–(2,6–
ditert–butylphenol)
118–82–1 NC S 88.7 91.3 268.7 NC NC NC 94.7 99.6 289 NC NC NC 89.5 100.6 279.6 NC NC NC
36 Sodium bisulfite 7631–90–5 NC S 78 41.5 197.5 NC NC NC 90.2 45.1 225.5 NC NC NC 98.5 49.3 246.3 NC NC NC
37 10–Undecenoic acid 112–38–9 NC S 86.7 51.6 225 NC NC NC 102.7 87 292.4 NC NC NC 99.7 80.1 279.5 NC NC NC
38 N,N–Dimethylbenzylamine 103–83–3 1BC L 74.2 2.8 77 1BC 1BC 1BC 88.7 5.1 93.8 1BC 1BC 1BC 95.2 0.5 95.7 1BC 1BC 1BC
39 Fluoboric acid 
(hydrogentetrafluoroborate) 
(48%)
16872–11–0 1BC L 12 6.9 12 1A 1A 1A 9 3.8 9 1A 1A 1A 9.1 7.7 9.1 1A 1A 1A
40 Maleic anhydride 108–31–6 1BC S 45.9 0.8 45.9 1A 1BC 1BC 70.4 0.7 71.1 1BC 1BC 1BC 64.4 0.7 65.1 1BC 1BC 1BC
41 60/40 octanoic/decanoc acid 68937–75–7 1BC L 63.2 8 71.2 1BC 1BC 1BC 67.4 5.4 72.8 1BC 1BC 1BC 67.4 8.2 75.6 1BC 1BC 1BC
42 55/45 octanoic/decanoc acid 68937–75–7 1BC L 66.4 7.5 73.9 1BC 1BC 1BC 72.7 5.3 78 1BC 1BC 1BC 68.9 7.9 76.8 1BC 1BC 1BC
43 65/35 octanoic/decanoic 
acid
68937–75–7 1BC L 75.7 7.4 83.1 1BC 1BC 1BC 76.4 6.6 83 1BC 1BC 1BC 75.1 7.6 82.7 1BC 1BC 1BC
44 N,N–Dimethylisopropylamine 996–35–0 1BC L 62.2 11.2 73.4 1BC 1BC 1BC 70 11.4 81.4 1BC 1BC 1BC 84.9 –1.5 83.4 1BC 1BC 1BC
45 Hydrochloric acid (14.4%) 7647–01–0 1BC L 80.8 9 89.8 1BC 1BC 1BC 65.4 8 73.4 1BC 1BC 1BC 82.8 9.2 92 1BC 1BC 1BC
(continued on next page)
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46 n–Heptylamine 111–68–2 1BC L 39.5 69.1 39.5 1A 1BC 1BC 25.9 27.2 25.9 1A 1BC 1BC 36.2 31.9 36.2 1A 1BC 1BC
47 Octanoic acid (caprylic acid) 124–07–2 1BC L 47.5 9.1 47.5 1A 1BC 1BC 53.7 13 66.7 1BC 1BC 1BC 39.4 10.4 39.4 1A 1BC 1BC
48 Carvacrol 499–75–2 1BC L 24 21.7 24 1A 1A 1A 68.4 –17.4 51 1BC 1BC 1BC 31.5 0.6 31.5 1A 1BC 1BC
49 2–Tert–Butylphenol 88–18–6 1BC L 22 –4.5 22 1A 1A 1A 31.5 8.2 31.5 1A 1BC 1BC 12 2.5 12 1A 1A 1A
50 Methacrolein 78–85–3 1BC L 77.6 5.5 83.1 1BC 1BC 1BC 40.9 20.5 40.9 1A 1BC 1BC 71.9 7 78.9 1BC 1BC 1BC
51 Lactic acid 598–82–3 1BC L 90 3.5 93.5 1BC 1BC 1BC 72.8 7.5 80.3 1BC 1BC 1BC 99 3.9 102.9 1BC 1BC 1BC
52 Sodium bisulphate 
monohydrate
10034–88–5 1BC S 80.6 9.6 90.2 1BC 1BC 1BC 79.7 14.8 94.5 1BC 1BC 1BC 93.8 7.5 101.3 1BC 1BC 1BC
53 Glyoxylic acid monohydrate 563–96–2 1BC S 90.4 3.1 93.5 1BC 1BC 1BC 80 3.2 83.2 1BC 1BC 1BC 102.1 2 104.1 1BC 1BC 1BC
54 Sodium bisulphate 7681–38–1 1BC S 82.6 10.1 92.7 1BC 1BC 1BC 85.6 14.3 99.9 1BC 1BC 1BC 104.5 9.7 114.2 1BC 1BC 1BC
55 Cyclohexylamine 108–91–8 1BC L 20.6 9.3 20.6 1A 1A 1A 22.6 11.1 22.6 1A 1A 1A 17.9 7.9 17.9 1A 1A 1A
56 2–Methylbutyric acid 600–07–7 1BC L 18.7 5 18.7 1A 1A 1A 17.2 19.6 17.2 1A 1BC 1A 9.7 4.9 9.7 1A 1A 1A
57 Glycol bromoacetate (85%) 3785–34–0 1BC L 79.4 11.6 91 1BC 1BC 1BC 71.3 13.8 85.1 1BC 1BC 1BC 70.5 11.1 81.6 1BC 1BC 1BC
58 3–Methoxypropylamine 5332–73–0 1BC L 6.7 6.1 6.7 1A 1A 1A 9.3 4.5 9.3 1A 1A 1A 7.7 3.8 7.7 1A 1A 1A
59 Allyl bromide 106–95–6 1BC L 100.2 13.3 113.5 1BC 1BC 1BC 95.1 4.6 99.7 1BC 1BC 1BC 91.2 4.2 95.4 1BC 1BC 1BC
60 1–(2–Aminoethyl)piperazine 140–31–8 1BC L 77.6 7 84.6 1BC 1BC 1BC 76.4 8.5 84.9 1BC 1BC 1BC 93.3 7.4 100.7 1BC 1BC 1BC
61 Iron(III) chloride 7705–08–0 1BC S 37.3 13.8 37.3 1A 1BC 1BC 64.5 6.2 70.7 1BC 1BC 1BC 39.8 12.3 39.8 1A 1BC 1BC
62 Phosphoric acid 7664–38–2 1BC L 37.5 5.2 37.5 1A 1BC 1BC 89.5 5.8 95.3 1BC 1BC 1BC 60.5 2.6 63.1 1BC 1BC 1BC
63 Propionic acid 79–09–4 1BC L 6.2 7.7 6.2 1A 1A 1A 4.7 6 4.7 1A 1A 1A 13.5 17.3 13.5 1A 1A 1A
64 Butyric acid 107–92–6 1BC L 6.9 3.2 6.9 1A 1A 1A 6 2.4 6 1A 1A 1A 13.2 6.7 13.2 1A 1A 1A
65 Boron trifluoride–acetic acid 
complex
373–61–5 1BC L 13.1 6.3 13.1 1A 1A 1A 7.8 6.7 7.8 1A 1A 1A 3.7 6 3.7 1A 1A 1A
66 Ethanolamine 141–43–5 1BC V 69.7 9.3 79 1BC 1BC 1BC 62.5 11 73.5 1BC 1BC 1BC 65.8 10.4 76.2 1BC 1BC 1BC
67 Hydrobromic acid (48%) 10035–10–6 1BC L 7.6 7 7.6 1A 1A 1A 9.7 10 9.7 1A 1A 1A 3.7 9 3.7 1A 1A 1A
68 HCl + sulphuric acid + citric 
acid (5, 5, 5 wt%)
– 1BC L 73.4 12.6 86 1BC 1BC 1BC 90.8 7.6 98.4 1BC 1BC 1BC 90.8 7.6 98.4 1BC 1BC 1BC
69 1,2–Diaminopropane 78–90–0 1A L 22 14.1 22 1A 1A 1A 37 24.3 37 1A 1BC 1BC 30.2 16.2 30.2 1A 1BC 1BC
70 Phosphorus tribromide 7789–60–8 1A L 0.6 1.2 0.6 1A 1A 1A 0.8 0.6 0.8 1A 1A 1A 6.2 3.9 6.2 1A 1A 1A
71 Boron trifluoride dihydrate 13319–75–0 1A L 4.4 10.1 4.4 1A 1A 1A 4.2 20.5 4.2 1A 1A 1A 7 6.7 7 1A 1A 1A
72 Acrylic acid 79–10–7 1A L 11 11.5 11 1A 1A 1A 12.1 14 12.1 1A 1A 1A 5.5 4.2 5.5 1A 1A 1A
73 Formic acid 64–18–6 1A L 6.9 13.4 6.9 1A 1A 1A 6.5 4.5 6.5 1A 1A 1A 3.4 6.7 3.4 1A 1A 1A
74 Dichloroacetyl chloride 79–36–7 1A L 1.3 1.4 1.3 1A 1A 1A 1.4 1.8 1.4 1A 1A 1A 0.5 0.9 0.5 1A 1A 1A
75 Silver nitrate 7761–88–8 1A S 11.2 10.2 11.2 1A 1A 1A 19.6 23.2 19.6 1A 1A 1A 5.2 3.5 5.2 1A 1A 1A
76 Phenol 108–95–2 1A S 22.6 13.5 22.6 1A 1A 1A 43 35 43 1A 1BC 1BC 10.3 10.3 10.3 1A 1A 1A
Table 9 (continued)
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77 Acetic acid 64–19–7 1A L 12.6 13.3 12.6 1A 1A 1A 15.6 22.4 15.6 1A 1A 1A 6 7.5 6 1A 1A 1A
78 Bromoacetic acid 79–08–3 1A S 3.2 2.8 3.2 1A 1A 1A 4.2 4.2 4.2 1A 1A 1A 3.3 3.6 3.3 1A 1A 1A
79 N,N–dimethy–
ldipropylenetriamine
10563–29–8 1A L 56 1.4 57.4 1BC 1BC 1BC 52.3 11.2 63.5 1BC 1BC 1BC 95.8 5.5 101.3 1BC 1BC 1BC
80 Sulphuric acid (98%) 7664–93–9 1A L 3.7 4.3 3.7 1A 1A 1A 3.2 3 3.2 1A 1A 1A 3.1 2.7 3.1 1A 1A 1A
SkinEthic™ RHE
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1 o–Methoxyphenol (guaiacol) 90–05–1 NC L 119.3 3.6 122.9 1BC 1BC 1BC 67.1 2.2 69.3 1BC 1BC 1BC 80.6 3.2 83.8 1BC 1BC 1BC
2 2,4–Xylidine (2,4–dimethylaniline) 95–68–1 NC L 55.4 0 55.4 1BC 1BC 1BC 45.8 4.1 45.8 1A 1BC 1BC 88.8 0 88.8 1BC 1BC 1BC
3 Phenethyl bromide (2–bromoethy  
benzene)
103–63–9 NC L 103.4 83.2 290 NC NC NC 106.9 86.6 300.4 NC NC NC 123.6 61.6 308.8 NC NC NC
4 Butyl carbamate 592–35–8 NC S 100.8 65.9 267.5 NC NC NC 86.5 4.9 91.4 1BC 1BC 1BC 103.2 6.7 109.9 1BC 1BC 1BC
5 L–Glutamic acid hydrochloride 138–15–8 NC S 100.3 16.7 217.3 NC NC NC 89.1 32.8 211 NC NC NC 114.1 15.3 243.5 NC NC NC
6 1–(o–Tolyl)biguanide 93–69–6 NC S 91.3 93.9 276.5 NC NC NC 80.6 82.5 243.7 NC NC NC 94.2 81.5 269.9 NC NC NC
7 Butyl glycolate (polysolvan) 7397–62–8 NC L 111.2 26.4 248.8 NC NC NC 100.3 11.8 112.1 1BC 1BC 1BC 101.4 3.7 105.1 1BC 1BC 1BC
8 2–Hydroxyisobutyiricacid 594–61–6 NC S 127.6 0.4 128 1BC 1BC 1BC 97.7 0.4 98.1 1BC 1BC 1BC 107.4 0.9 108.3 1BC 1BC 1BC
9 Oxalic acid dihydrate 6153–56–6 NC S 112.2 0.5 112.7 1BC 1BC 1BC 86.1 0.5 86.6 1BC 1BC 1BC 103.8 0.8 104.6 1BC 1BC 1BC
10 Alpha–Ketoglutaric acid 328–50–7 NC S 85.8 0.4 86.2 1BC 1BC 1BC 74.4 0.2 74.6 1BC 1BC 1BC 32.6 1.5 32.6 1A 1BC 1BC
11 Sulphamic acid 5329–14–6 NC S 92.2 38.2 222.6 NC NC NC 96.6 96.6 289.8 NC NC NC 62 2.2 64.2 1BC 1BC 1BC
12 Dodecanoic acid (lauric acid) 143–07–7 NC S 111.3 82.7 305.3 NC NC NC 103.6 76 283.2 NC NC NC 95.5 54.8 245.8 NC NC NC
13 Sodium lauryl sulphate (20%) 151–21–3 NC L 99 72.3 270.3 NC NC NC 101.9 77 280.8 NC NC NC 101.7 93.5 296.9 NC NC NC
14 Methyl trimethylacetate 598–98–1 NC L 97.4 37.2 232 NC NC NC 103.9 48.6 256.4 NC NC NC 92 25.1 209.1 NC NC NC
15 4–Amino–4H–1,2,4–triazole 584–13–4 NC S 106 91.9 303.9 NC NC NC 97.5 106.6 301.6 NC NC NC 96.2 88.1 280.5 NC NC NC
16 1,9–Decadiene 1647–16–1 NC L 101.1 73.3 275.5 NC NC NC 86.4 82.8 255.6 NC NC NC 100.6 67.3 268.5 NC NC NC
(continued on next page)
2063
B.D
esprez
etal./Toxicology
in
V
itro
29
(2015)
2055–2080
17 Sodium carbonate (50%) 497–19–8 NC L 111 104.3 326.3 NC NC NC 95.7 82 273.4 NC NC NC 117.1 91.7 325.9 NC NC NC
18 Benzylacetone (4–phenyl–2–
butanone)
2550–26–7 NC L 86.6 67.4 240.6 NC NC NC 93.6 56.8 244 NC NC NC 94.9 65.7 255.5 NC NC NC
19 Eugenol 97–53–0 NC L 60.5 5 65.5 1BC 1BC 1BC 43.5 16.2 43.5 1A 1BC 1BC 86.9 0 86.9 1BC 1BC 1BC
20 Tetrachloroethylene 127–18–4 NC L 115.1 28.7 258.9 NC NC NC 87.4 37 211.8 NC NC NC 102.5 17.8 222.8 NC NC NC
21 Sodium undecylenate (33%) 3398–33–2 NC L 98 4.3 102.3 1BC 1BC 1BC 65.5 3.9 69.4 1BC 1BC 1BC 78.3 5.7 84 1BC 1BC 1BC
22 4–Amino–5–methoxy–2–
methylbenzensulphonic acid
6471–78–9 NC S 100.8 99.4 301 NC NC NC 111.7 105.9 329.3 NC NC NC 103.6 65.5 272.7 NC NC NC
23 Potassium hydroxide (5%) 1310–58–3 NC L 92.4 0 92.4 1BC 1BC 1BC 79.5 0 79.5 1BC 1BC 1BC 82.9 0 82.9 1BC 1BC 1BC
24 3,3–Dithiopropionic acid 1119–62–6 NC S 92.1 89.2 273.4 NC NC NC 102.2 93.2 297.6 NC NC NC 102.6 99.4 304.6 NC NC NC
25 Isopropanol 67–63–0 NC L 114 90.1 318.1 NC NC NC 82.7 75 240.4 NC NC NC 113.3 87.6 314.2 NC NC NC
26 2–Phenylalcohol (2–Phenetyl 
ethanol)
60–12–8 NC L 95.4 23.6 214.4 NC NC NC 99.8 30.9 230.5 NC NC NC 105.4 2.1 107.5 1BC 1BC 1BC
27 n–Butyl propionate 590–01–2 NC L 90.2 50.7 231.1 NC NC NC 73.5 36.8 183.8 NC NC NC 84.5 33.5 202.5 NC NC NC
28 Methyl palmitate 112–39–0 NC S 119.9 115.4 355.2 NC NC NC 109 102.1 320.1 NC NC NC 108 141.3 357.3 NC NC NC
29 Methyl laurate 111–82–0 NC L 92.4 84.5 269.3 NC NC NC 127.6 123.8 379 NC NC NC 90.1 102.1 282.3 NC NC NC
30 Sodium bicarbonate 144–55–8 NC S 92.5 94 279 NC NC NC 98.1 103.6 299.8 NC NC NC 106.2 118.8 331.2 NC NC NC
31 2–Bromobutane 78–76–2 NC L 93.3 26.4 213 NC NC NC 101.6 40.7 243.9 NC NC NC 98.7 16.7 214.1 NC NC NC
32 4–(Methylthio)–benzaldehyde 3446–89–7 NC L 97.9 90 285.8 NC NC NC 97.8 59.3 254.9 NC NC NC 122.1 78 322.2 NC NC NC
33 2–Ethoxyethyl methacrylate 2370–63–0 NC L 90.5 58.4 239.4 NC NC NC 77.4 55 209.8 NC NC NC 86.3 50.8 223.4 NC NC NC
34 Cinnamaldehyde 14371–10–9 NC L 72.8 37.2 182.8 NC NC NC 86.4 15.1 187.9 NC NC NC 57.4 19.6 134.4 NC NC NC
35 4,4´–Methylene–bis–(2,6–ditert–
butylphenol)
118–82–1 NC S 104 107 315 NC NC NC 98.1 95.6 291.8 NC NC NC 111.3 89.5 312.1 NC NC NC
36 Sodium bislufite 7631–90–5 NC S 112.8 68.3 293.9 NC NC NC 121.9 98.3 342.1 NC NC NC 93.1 20.4 206.6 NC NC NC
37 10–Undecenoic acid 112–38–9 NC S 62.1 54.8 179 NC NC NC 111.5 81.4 304.4 NC NC NC 80.6 16.7 177.9 NC NC NC
38 N,N–Dimethylbenzylamine 103–83–3 1BC L 63.5 0.2 63.7 1BC 1BC 1BC 62.1 8.4 70.5 1BC 1BC 1BC 40.6 10.1 40.6 1A 1BC 1BC
39 Fluoboric acid 
(hydrogentetrafluoroborate) (48%)
16872–11–0 1BC L 25.6 0.6 25.6 1A 1BC 1BC 26.7 0.3 26.7 1A 1BC 1BC 25.5 0.1 25.5 1A 1BC 1BC
40 Maleic anhydride 108–31–6 1BC S 62.2 0.2 62.4 1BC 1BC 1BC 40.2 0.1 40.2 1A 1BC 1BC 51.5 0.2 51.7 1BC 1BC 1BC
41 60/40 octanoic/decanoc acid 68937–75–7 1BC L 53.2 5.9 59.1 1BC 1BC 1BC 55.6 3.3 58.9 1BC 1BC 1BC 78 7.6 85.6 1BC 1BC 1BC
42 55/45 octanoic/decanoc acid 68937–75–7 1BC L 64.5 8.3 72.8 1BC 1BC 1BC 57 4 61 1BC 1BC 1BC 61.2 3.3 64.5 1BC 1BC 1BC
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43 65/35 octanoic/decanoic acid 68937–75–7 1BC L 51.8 5.7 57.5 1BC 1BC 1BC 59.3 2.6 61.9 1BC 1BC 1BC 60.9 4.3 65.2 1BC 1BC 1BC
44 N,N–dimethylisopropylamine 996–35–0 1BC L 3.9 4.1 3.9 1A 1A 1A 44.8 3.1 44.8 1A 1BC 1BC 19.8 3.1 19.8 1A 1BC 1BC
45 Hydrochloric acid (14.4%) 7647–01–0 1BC L 97.2 1.5 98.7 1BC 1BC 1BC 88 0.5 88.5 1BC 1BC 1BC 90.6 3.8 94.4 1BC 1BC 1BC
46 n–Heptylamine 111–68–2 1BC L 0 0 0 1A 1A 1A 0 0 0 1A 1A 1A 0 0 0 1A 1A 1A
47 Octanoic acid (caprylic acid) 124–07–2 1BC L 27.8 2.3 27.8 1A 1BC 1BC 63.9 2.4 66.3 1BC 1BC 1BC 19.1 1.7 19.1 1A 1BC 1BC
48 Carvacrol 499–75–2 1BC L 15.7 9.8 15.7 1A 1A 1A 12.9 0.3 12.9 1A 1A 1A 31 4.6 31 1A 1BC 1BC
49 2–tert–Butylphenol 88–18–6 1BC L 8.6 0 8.6 1A 1A 1A 2.4 3.3 2.4 1A 1A 1A 2.3 0 2.3 1A 1A 1A
50 Methacrolein 78–85–3 1BC L 59.6 5.2 64.8 1BC 1BC 1BC 54.1 6.2 60.3 1BC 1BC 1BC 63.3 10.7 74 1BC 1BC 1BC
51 Lactic acid 598–82–3 1BC L 76.3 1.9 78.2 1BC 1BC 1BC 76.7 0.4 77.1 1BC 1BC 1BC 91.2 0.4 91.6 1BC 1BC 1BC
52 Sodium bisulphate monohydrate 10034–88–5 1BC S 121.3 4.2 125.5 1BC 1BC 1BC 109.7 9.9 119.6 1BC 1BC 1BC 110.4 84.5 305.3 NC NC NC
53 Glyoxylic acid monohydrate 563–96–2 1BC S 82.1 0.3 82.4 1BC 1BC 1BC 94.8 0.2 95 1BC 1BC 1BC 100.3 0.3 100.6 1BC 1BC 1BC
54 Sodium bisulphate 7681–38–1 1BC S 123.8 4.9 128.7 1BC 1BC 1BC 105.8 10.6 116.4 1BC 1BC 1BC 92.1 6.2 98.3 1BC 1BC 1BC
55 Cyclohexylamine 108–91–8 1BC L 4.4 2.4 4.4 1A 1A 1A 9.5 1.4 9.5 1A 1A 1A 6.7 3 6.7 1A 1A 1A
56 2–Methylbutyric acid 600–07–7 1BC L 3.1 1.1 3.1 1A 1A 1A 6.1 0 6.1 1A 1A 1A 18.6 2.1 18.6 1A 1BC 1BC
57 Glycol bromoacetate (85%) 3785–34–0 1BC L 70.1 0.6 70.7 1BC 1BC 1BC 62.6 0.6 63.2 1BC 1BC 1BC 59.3 0.4 59.7 1BC 1BC 1BC
58 3–Methoxypropylamine 5332–73–0 1BC L 13.9 20.1 13.9 1A 1A 1A 16.6 1.7 16.6 1A 1A 1A 9.2 0 9.2 1A 1A 1A
59 Allyl bromide 106–95–6 1BC L 48.9 1.6 48.9 1A 1BC 1BC 45.8 1.4 45.8 1A 1BC 1BC 45 2.3 45 1A 1BC 1BC
60 1–(2–Aminoethyl)piperazine 140–31–8 1BC L 97 48.3 242.3 NC NC NC 95.3 66.5 257.1 NC NC NC 86.5 58.6 231.6 NC NC NC
61 Iron(III) chloride 7705–08–0 1BC S 102.6 43.4 248.6 NC NC NC 89.8 101.1 280.7 NC NC NC 93.5 83.7 270.7 NC NC NC
62 Phosphoric acid 7664–38–2 1BC L 84.1 1.8 85.9 1BC 1BC 1BC 82 1 83 1BC 1BC 1BC 119.8 0.3 120.1 1BC 1BC 1BC
63 Propionic acid 79–09–4 1BC L 1.7 4.8 1.7 1A 1A 1A 4.1 3.9 4.1 1A 1A 1A 2.2 2.6 2.2 1A 1A 1A
64 Butyric acid 107–92–6 1BC L 4.1 3.3 4.1 1A 1A 1A 4.7 1.6 4.7 1A 1A 1A 1.8 0.8 1.8 1A 1A 1A
65 Boron trifluoride–acetic acid complex 373–61–5 1BC L 5.5 3.1 5.5 1A 1A 1A 1.1 2.5 1.1 1A 1A 1A 0.2 0.9 0.2 1A 1A 1A
66 Ethanolamine 141–43–5 1BC V 73.8 0.7 74.5 1BC 1BC 1BC 86.5 5.6 92.1 1BC 1BC 1BC 59.2 0 59.2 1BC 1BC 1BC
67 Hydrobromic acid (48%)  10035–10–6 1BC L 4.7 3.6 4.7 1A 1A 1A 0.1 1.8 0.1 1A 1A 1A 2.9 0.8 2.9 1A 1A 1A
68 HCl + sulphuric acid + citric acid (5, 5, 
5 wt.% )
– 1BC L 96.3 2.8 99.1 1BC 1BC 1BC 104 2 106 1BC 1BC 1BC 100.4 2.8 103.2 1BC 1BC 1BC
69 1,2–Diaminopropane 78–90–0 1A L 63.3 0 63.3 1BC 1BC 1BC 69.1 6.2 75.3 1BC 1BC 1BC 17.5 6.6 17.5 1A 1A 1A
70 Phosphorus tribromide 7789–60–8 1A L 0.7 1.7 0.7 1A 1A 1A 0.9 0.8 0.9 1A 1A 1A 0.4 0.4 0.4 1A 1A 1A
71 Boron trifluoride dihydrate 13319–75–0 1A L 0.1 0 0.1 1A 1A 1A 0.1 0 0.1 1A 1A 1A 1.5 3.7 1.5 1A 1A 1A
(continued on next page)
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72 Acrylic acid 79–10–7 1A L 2.3 1.6 2.3 1A 1A 1A 0.6 1.1 0.6 1A 1A 1A 2.7 1.9 2.7 1A 1A 1A
73 Formic acid 64–18–6 1A L 1.9 2.8 1.9 1A 1A 1A 1.2 3.2 1.2 1A 1A 1A 2.3 3.5 2.3 1A 1A 1A
74 Dichloroacetyl chloride 79–36–7 1A L 0.3 0.8 0.3 1A 1A 1A 0.4 2.3 0.4 1A 1A 1A 0.1 0.1 0.1 1A 1A 1A
75 Silver nitrate 7761–88–8 1A S 3.1 9.5 3.1 1A 1A 1A 31.7 11.2 31.7 1A 1BC 1BC 5 15.3 5 1A 1A 1A
76 Phenol 108–95–2 1A S 10.2 6.2 10.2 1A 1A 1A 6 5 6 1A 1A 1A 6.5 4.3 6.5 1A 1A 1A
77 Acetic acid 64–19–7 1A L 2.2 2.7 2.2 1A 1A 1A 2.3 0.8 2.3 1A 1A 1A 1.1 2 1.1 1A 1A 1A
78 Bromoacetic acid 79–08–3 1A S 1 2.6 1 1A 1A 1A 2.2 2.3 2.2 1A 1A 1A 2.2 2.9 2.2 1A 1A 1A
79 N,N–Dimethyl–dipropylenetriamine 10563–29–8 1A L 100.5 7.6 108.1 1BC 1BC 1BC 83.6 5.7 89.3 1BC 1BC 1BC 91.7 4.3 96 1BC 1BC 1BC
80 Sulphuric acid (98%) 7664–93–9 1A L 1.4 1.4 1.4 1A 1A 1A 1.2 1.3 1.2 1A 1A 1A 2.4 0.7 2.4 1A 1A 1A
epiCS®
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1 o–Methoxyphenol (guaiacol) 90–05–1 NC L 77.75 9.09 86.84 1BC 1BC 1BC 98.31 1.79 100.1 1BC 1BC 1BC
2 2,4–Xylidine (2,4–dimethylaniline) 95–68–1 NC L 91.2 22.44 204.84 NC NC NC 84.1 2.8 86.9 1BC 1BC 1BC
3 Phenethyl bromide (2–bromoethy benzene) 103–63–9 NC L 93.97 55.26 243.2 NC NC NC 80.87 58.81 220.55 NC NC NC
4 Butyl carbamate 592–35–8 NC S 116.29 64.6 297.18 NC NC NC 150.7 46.2 347.6 NC NC NC
5 L–Glutamic acid hydrochloride 138–15–8 NC S 130.3 126.5 387.1 NC NC NC 151.5 144.4 447.4 NC NC NC
6 1–(o–Tolyl)biguanide 93–69–6 NC S 101.87 98 301.74 NC NC NC 97.57 76.28 271.42 NC NC NC
7 Butyl glycolate (polysolvan) 7397–62–8 NC L 101.49 8.6 110.09 1BC 1BC 1BC 105 8.84 113.84 1BC 1BC 1BC
8 2–Hydroxyisobutyiric acid 594–61–6 NC S 64.11 2.48 66.59 1BC 1BC 1BC 57.83 2.85 60.68 1BC 1BC 1BC
9 Oxalic acid dihydrate 6153–56–6 NC S 108.2 8.2 116.4 1BC 1BC 1BC 116.6 3.8 120.4 1BC 1BC 1BC
10 alpha–Ketoglutaric acid 328–50–7 NC S 94.4 3.3 97.7 1BC 1BC 1BC 106.1 3.8 109.9 1BC 1BC 1BC
11 Sulphamic acid 5329–14–6 NC S 104 2.9 106.9 1BC 1BC 1BC 105.1 3.8 108.9 1BC 1BC 1BC
12 Dodecanoic acid (lauric acid) 143–07–7 NC S 104.29 93.05 301.63 NC NC NC 94.34 76 264.68 NC NC NC
13 Sodium lauryl sulphate (20%) 151–21–3 NC L 84.49 62.56 231.54 NC NC NC 114.69 51.64 281.02 NC NC NC
14 Methyl trimethylacetate 598–98–1 NC L 93 22.69 208.69 NC NC NC 113.61 18.64 245.86 NC NC NC
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15 4–Amino–4H–1,2,4–triazole 584–13–4 NC S 98 81 277 NC NC NC 106.9 94 307.8 NC NC NC
16 1,9–Decadiene 1647–16–1 NC L 87.03 16.57 190.63 NC NC NC 104.82 82.06 291.7 NC NC NC
17 Sodium carbonate (50%) 497–19–8 NC L 89.4 98.6 277.4 NC NC NC 90.9 52.3 234.1 NC NC NC
18 Benzylacetone (4–phenyl–2–butanone) 2550–26–7 NC L 76.57 44.87 198.01 NC NC NC 83.68 55.74 223.1 NC NC NC
19 Eugenol 97–53–0 NC L 92.65 28.63 213.93 NC NC NC 63.05 20.61 146.71 NC NC NC
20 Tetrachloroethylene 127–18–4 NC L 87.22 27.5 201.94 NC NC NC 88.2 19.6 196 NC NC NC
21 Sodium undecylenate (33%) 3398–33–2 NC L 69.81 7.13 76.93999 1BC 1BC 1BC 72.68 8.56 81.24 1BC 1BC 1BC
22 4–Amino–5–methoxy–2–methylbenzensulphonic acid 6471–78–9 NC S 100.57 111.03 312.17 NC NC NC 106.27 113.09 325.63 NC NC NC
23 Potassium hydroxide (5%) 1310–58–3 NC L 91.23 –1.23 90 1BC 1BC 1BC 62.26 6.66 68.92 1BC 1BC 1BC
24 3,3–Dithiopropionic acid 1119–62–6 NC S 91.01 108.71 290.73 NC NC NC 109.88 120.34 340.1 NC NC NC
25 Isopropanol 67–63–0 NC L 103.83 119.94 327.6 NC NC NC 98.76 106.08 303.6 NC NC NC
26 2–Phenylalcohol (2–Phenetyl etanol) 60–12–8 NC L 102.3 1.66 103.96 1BC 1BC 1BC 99.19 1.89 101.08 1BC 1BC 1BC
27 n–Butyl propionate 590–01–2 NC L 100.43 19.46 220.32 NC NC NC 70.77 17.72 159.26 NC NC NC
28 Methyl palmitate 112–39–0 NC S 93.91 100.11 287.93 NC NC NC 102.39 112.48 317.26 NC NC NC
29 Methyl laurate 111–82–0 NC L 106.58 98.38 311.54 NC NC NC 94.1 98.25 286.45 NC NC NC
30 Sodium bicarbonate 144–55–8 NC S 97.8 103 298.6 NC NC NC 128.8 129.9 387.5 NC NC NC
31 2–Bromobutane 78–76–2 NC L 78.03 21.88 177.94 NC NC NC 74.61 16.97 166.19 NC NC NC
32 4–(Methylthio)–benzaldehyde 3446–89–7 NC L 89.34 62.32 241 NC NC NC 83.89 71.52 239.3 NC NC NC
33 2–Ethoxyethyl methacrylate 2370–63–0 NC L 94.97 59.74 249.68 NC NC NC 86.08 36.04 208.2 NC NC NC
34 Cinnamaldehyde 14371–10–9 NC L 76.73 13.31 90.04 1BC 1BC 1BC 91.1 4.47 95.57 1BC 1BC 1BC
35 4,4'–Methylene–bis–(2,6–ditert–butylphenol) 118–82–1 NC S 93.06 87.95 274.07 NC NC NC 101.73 112.69 316.15 NC NC NC
36 Sodium bislufite 7631–90–5 NC S 103.76 91.51 299.03 NC NC NC 86.49 77.25 250.23 NC NC NC
37 10–Undecenoic acid 112–38–9 NC S 69.33 34.47 173.13 NC NC NC 63.88 15.86 143.62 NC NC NC
38 N,N–Dimethylbenzylamine 103–83–3 1BC L 27.35 1.3 27.35 1A 1BC 1BC 31.82 6.07 31.82 1A 1BC 1BC
39 Fluoboric acid (hydrogentetrafluoroborate) (48%) 16872–11–0 1BC L 1.99 1.96 1.99 1A 1A 1A 2.97 2.68 2.97 1A 1A 1A
40 Maleic anhydride 108–31–6 1BC S 26.12 3.8 26.12 1A 1BC 1BC 85.62 2.64 88.26 1BC 1BC 1BC
41 60/40 Octanoic/decanoc acid 68937–75–7 1BC L 50.48 5.36 55.84 1BC 1BC 1BC 51.03 5.58 56.61 1BC 1BC 1BC
42 55/45 Octanoic/decanoc acid 68937–75–7 1BC L 57.09 6.29 63.38 1BC 1BC 1BC 68.36 5.65 74.01 1BC 1BC 1BC
43 65/35 Octanoic/decanoic acid 68937–75–7 1BC L 51.91 4.42 56.33 1BC 1BC 1BC 52.34 4.8 57.14 1BC 1BC 1BC
44 N,N–Dimethylisopropylamine 996–35–0 1BC L 61.86 –1.41 60.45 1BC 1BC 1BC 86.71 10.69 97.4 1BC 1BC 1BC
45 Hydrochloric acid (14.4%) 7647–01–0 1BC L 84.13 2.93 87.06 1BC 1BC 1BC 58.58 5.9 64.48 1BC 1BC 1BC
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46 n–Heptylamine 111–68–2 1BC L –13.73 8.31 –13.73 1A 1A 1A 23.2 6.46 23.2 1A 1BC 1BC
47 Octanoic acid (caprylic acid) 124–07–2 1BC L 27.32 3.03 27.32 1A 1BC 1BC 23.2 2.9 23.2 1A 1BC 1BC
48 Carvacrol 499–75–2 1BC L 90.67 3.65 94.32 1BC 1BC 1BC 12.83 2.44 12.83 1A 1A 1A
49 2–tert–Butylphenol 88–18–6 1BC L 10.26 4.95 10.26 1A 1A 1A 7.36 –1.71 7.36 1A 1A 1A
50 Methacrolein 78–85–3 1BC L 58.2 0.9 59.1 1BC 1BC 1BC 66 3.8 69.8 1BC 1BC 1BC
51 Lactic acid 598–82–3 1BC L 74.81 0.01 74.82 1BC 1BC 1BC 86.05 2.24 88.29 1BC 1BC 1BC
52 Sodium bisulphate monohydrate 10034–88–5 1BC S 117.13 14.3 131.43 1BC 1BC NC 105.97 4.28 110.25 1BC 1BC 1BC
53 Glyoxylic acid monohydrate 563–96–2 1BC S 100.82 2.87 103.69 1BC 1BC 1BC 88.82 2.68 91.5 1BC 1BC 1BC
54 Sodium bisulphate 7681–38–1 1BC S 86.28 84.64 257.2 NC NC NC 90.54 97.1 278.18 NC NC NC
55 Cyclohexylamine 108–91–8 1BC L 0.61 0.1 0.61 1A 1A 1A 0.53 1.31 0.53 1A 1A 1A
56 2–Methylbutyric acid 600–07–7 1BC L 7.39 2.39 7.39 1A 1A 1A 4.17 2.44 4.17 1A 1A 1A
57 Glycol bromoacetate (85%) 3785–34–0 1BC L 53.82 0.25 54.07 1BC 1BC 1BC
58 3–Methoxypropylamine 5332–73–0 1BC L 10.87 0.67 10.87 1A 1A 1A 6.62 4.76 6.62 1A 1A 1A
59 Allyl bromide 106–95–6 1BC L 83.08 13.14 96.22 1BC 1BC 1BC 57.87 3.48 61.35 1BC 1BC 1BC
60 1–(2–Aminoethyl)piperazine 140–31–8 1BC L 102.09 13.47 115.56 1BC 1BC 1BC 77.87 3.44 81.31 1BC 1BC 1BC
61 Iron(III) chloride 7705–08–0 1BC S 106.13 103.66 315.92 NC NC NC 83.27 80.26 246.8 NC NC NC
62 Phosphoric acid 7664–38–2 1BC L 35.77 3.7 35.77 1A 1BC 1BC 7.78 2.48 7.78 1A 1A 1A
63 Propionic acid 79–09–4 1BC L 2.94 3.22 2.94 1A 1A 1A 2.26 4.42 2.26 1A 1A 1A
64 Butyric acid 107–92–6 1BC L 0.6 0.18 0.6 1A 1A 1A 3.21 2.26 3.21 1A 1A 1A
65 Boron trifluoride–acetic acid complex 373–61–5 1BC L 1.8 3.96 1.8 1A 1A 1A 23.51 3.9 23.51 1A 1BC 1BC
66 Ethanolamine 141–43–5 1BC V 106.73 3.12 109.85 1BC 1BC 1BC 71.68 2.57 74.25 1BC 1BC 1BC
67 Hydrobromic acid (48%) 10035–10–6 1BC L 2.15 5.84 2.15 1A 1A 1A 1.95 5.09 1.95 1A 1A 1A
68 HCl + sulphuric acid + citric acid (5, 5, 5 wt.%) – 1BC L 97.54 2.99 100.53 1BC 1BC 1BC 102.93 4.97 107.9 1BC 1BC 1BC
69 1,2–Diaminopropane 78–90–0 1A L 2.89 4.33 2.89 1A 1A 1A 5.2 3.34 5.2 1A 1A 1A
70 Phosphorus tribromide 7789–60–8 1A L 14.91 1.02 14.91 1A 1A 1A 2.37 5.83 2.37 1A 1A 1A
71 Boron trifluoride dihydrate 13319–75–0 1A L 6.07 2.58 6.07 1A 1A 1A 12.02 3.66 12.02 1A 1A 1A
72 Acrylic acid 79–10–7 1A L 4.93 3.74 4.93 1A 1A 1A 3.56 2.45 3.56 1A 1A 1A
73 Formic acid 64–18–6 1A L 1.9 2.9 1.9 1A 1A 1A 1.74 3.36 1.74 1A 1A 1A
74 Dichloroacetyl chloride 79–36–7 1A L 1.59 1.65 1.59 1A 1A 1A 1.43 1.46 1.43 1A 1A 1A
75 Silver nitrate 7761–88–8 1A S 17.5 20.8 17.5 1A 1BC 1A 0.42 9.33 0.42 1A 1A 1A
76 Phenol 108–95–2 1A S 9.7 5.3 9.7 1A 1A 1A 9.66 4.84 9.66 1A 1A 1A
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77 Acetic acid 64–19–7 1A L 3.02 4.31 3.02 1A 1A 1A 2.35 4.21 2.35 1A 1A 1A
78 Bromoacetic acid 79–08–3 1A S 4.4 3.7 4.4 1A 1A 1A 2.28 3.42 2.28 1A 1A 1A
79 N,N–Dimethyl–dipropylenetriamine 10563–29–8 1A L 69.68 –1.01 68.67 1BC 1BC 1BC 85.7 6.62 92.32 1BC 1BC 1BC
80 Sulphuric acid (98%) 7664–93–9 1A L 2.8 2.33 2.8 1A 1A 1A 2.71 2.23 2.71 1A 1A 1A
EpiSkin™–results of EpiSkin™ are presented for the purpose of the ROC analysis performed on the basis of PMvar2
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1 o–Methoxyphenol (guaiacol) 90–05–1 NC L 109.5 64.8 36.1 538.9 NC NC 98.6 49.9 37.3 481.6 NC NC 83.7 35.5 15.7 134.9 1BC 1BC
2 2,4–Xylidine (2,4–
dimethylaniline)
95–68–1 NC L 109.8 101.2 31.2 242.2 1BC 1BC 124.5 98.3 77.7 674 NC NC 139.5 93.8 50.8 702.6 NC NC
3 Phenethyl bromide (2–
bromoethy benzene)
103–63–9 NC L 141 127.2 117.2 808.4 NC NC 144.7 137.5 139.4 855.7 NC NC 147.6 173 182.7 946.1 NC NC
4 Butyl carbamate 592–35–8 NC S 110.9 113.9 91.1 648.6 NC NC 108.5 112.1 86.2 632.3 NC NC 91.6 107.6 93.5 567.5 NC NC
5 L–Glutamic acid 
hydrochloride
138–15–8 NC S 106.7 84.2 33.6 224.5 1BC 1BC 95.3 90.2 68.6 540 NC NC 94.5 94 42.8 514.8 NC NC
6 1–(o–Tolyl)biguanide 93–69–6 NC S 115.6 110.3 104.9 677.6 NC NC 94.6 98.5 98.9 575.8 NC NC 94.6 107.1 104 589.5 NC NC
7 Butyl glycolate (polysolvan) 7397–62–8 NC L 110.9 108.2 82.6 634.4 NC NC 88.7 92.6 74.5 521.9 NC NC 96.1 105.7 94.1 584.2 NC NC
8 2–Hydroxyisobutyiric acid 594–61–6 NC S 94.7 42.6 5.4 142.7 1BC 1BC 95.5 41.4 3.7 140.6 1BC 1BC 103 35 6.7 144.7 1BC 1BC
9 Oxalic acid dihydrate 6153–56–6 NC S 103.6 38.9 4.2 146.7 1BC 1BC 91.5 51.9 17.5 160.9 1BC 1BC 109.6 50.3 6.4 166.3 1BC 1BC
10 alpha–Ketoglutaric acid 328–50–7 NC S 71.5 18.1 4.1 89.6 1BC 1BC 101.7 19.8 6.6 121.5 1BC 1BC 101.7 10.5 5.7 112.2 1BC 1BC
11 Sulphamic acid 5329–14–6 NC S 102.9 26.6 20.9 129.5 1BC 1BC 97.9 19.4 0.6 117.3 1BC 1BC 111.2 34.2 2.5 145.4 1BC 1BC
12 Dodecanoic acid (lauric acid) 143–07–7 NC S 102 117.4 120.8 646.2 NC NC 104 111.5 141.7 669.2 NC NC 104.6 94.4 108.4 621.2 NC NC
13 Sodium lauryl sulphate 
(20%)
151–21–3 NC L 104.9 100.1 79 598.7 NC NC 114 114.6 94.2 664.8 NC NC 89 90.2 80.6 526.8 NC NC
14 Methyl trimethylacetate 598–98–1 NC L 111.3 117.4 75.3 637.9 NC NC 106.5 100.9 94 620.9 NC NC 116.2 109.3 97.2 671.3 NC NC
15 4–Amino–4H–1,2,4–triazole 584–13–4 NC S 116.8 120.6 79.6 667.4 NC NC 105.9 106 99.4 629 NC NC 105 105.6 97.2 622.8 NC NC
16 1,9–Decadiene 1647–16–1 NC L 109.5 112.4 87.8 638.2 NC NC 114.3 136.3 126.7 720.2 NC NC 137.6 128.6 110.2 789.2 NC NC
17 Sodium carbonate (50%) 497–19–8 NC L 103.8 65.2 60.7 541.1 NC NC 140 107.5 44.7 712.2 NC NC 73.8 79 43.5 417.7 NC NC
(continued on next page)
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18 Benzylacetone (4–phenyl–2–
butanone)
2550–26–7 NC L 133.2 141.2 137.1 811.1 NC NC 134.7 151.3 149.9 840 NC NC 150.3 142.2 143.4 886.8 NC NC
19 Eugenol 97–53–0 NC L 188.4 122.3 42.7 918.6 NC NC 121.7 86 12.1 219.8 1BC 1BC 132.9 74.8 14.2 221.9 1BC 1BC
20 Tetrachloroethylene 127–18–4 NC L 106.5 88.4 68.5 582.9 NC NC 113.1 116.3 56.2 624.9 NC NC 112 97.4 75 620.4 NC NC
21 Sodium undecylenate (33%) 3398–33–2 NC L 137.6 36 10.7 184.3 1BC 1BC 127.7 40.2 11 178.9 1BC 1BC 149.7 55 16.5 221.2 1BC 1BC
22 4–Amino–5–methoxy–2–
methylbenzensulphonic acid
6471–78–9 NC S 99.9 115.6 98.6 613.8 NC NC 105.7 92.3 85.1 600.2 NC NC 98.2 112.6 101.2 606.6 NC NC
23 Potassium hydroxide (5%) 1310–58–3 NC L 72.3 24.6 16.5 96.9 1BC 1BC 68.5 30.1 14.6 98.6 1BC 1BC 94.8 18.9 26.8 113.7 1BC 1BC
24 3,3–Dithiopropionic acid 1119–62–6 NC S 113.4 117.5 105.8 676.9 NC NC 107.9 108.9 95.7 636.2 NC NC 110.3 102.1 113.1 656.4 NC NC
25 Isopropanol 67–63–0 NC L 98.9 84.4 88.5 568.5 NC NC 91.8 87.8 80.8 535.8 NC NC 98.1 100.2 94.7 587.3 NC NC
26 2–Phenylalcohol (2–Phenetyl 
etanol)
60–12–8 NC L 102.1 98.1 91.5 598 NC NC 110.5 108.3 126.1 676.4 NC NC 88.1 87.6 100.1 540.1 NC NC
27 n–Butyl propionate 590–01–2 NC L 106.3 80.5 58.7 564.4 NC NC 111.5 105.7 63.1 614.8 NC NC 95.3 70.4 47.9 499.5 NC NC
28 Methyl palmitate 112–39–0 NC S 108.3 105.3 97.2 635.7 NC NC 115.7 109.3 92.1 664.2 NC NC 96.5 80.1 103.1 569.2 NC NC
29 Methyl laurate 111–82–0 NC L 100.9 100.2 93.6 597.4 NC NC 102.4 95.8 100.5 605.9 NC NC 105.8 117.9 110.8 651.9 NC NC
30 Sodium bicarbonate 144–55–8 NC S 94.3 95.1 90.7 563 NC NC 105 102.1 115.3 637.4 NC NC 102.8 92.3 97.4 600.9 NC NC
31 2–Bromobutane 78–76–2 NC L 105.6 85.5 35.3 543.2 NC NC 101.8 95.1 103.2 605.5 NC NC 133.8 104 54.3 693.5 NC NC
32 4–(Methylthio)–
benzaldehyde
3446–89–7 NC L 136.7 150.4 138.1 835.3 NC NC 143.7 150.3 150.7 875.8 NC NC 142.2 158.3 154.2 881.3 NC NC
33 2–Ethoxyethyl methacrylate 2370–63–0 NC L 132 133.2 125.8 787 NC NC 142 139.6 164.5 872.1 NC NC 133.1 139.7 154.6 826.7 NC NC
34 Cinnamaldehyde 14371–10–9 NC L 142.1 125.1 99.3 792.8 NC NC 134.5 97.3 80 715.3 NC NC 138.5 94.2 48.8 697 NC NC
35 4,4´–Methylene–bis–(2,6–
ditert–butylphenol)
118–82–1 NC S 109.5 100.9 102.7 641.6 NC NC 110.3 104.8 100.7 646.7 NC NC 110.6 100.5 95.4 638.3 NC NC
36 Sodium bislufite 7631–90–5 NC S 94.9 67.6 42.3 489.5 NC NC 89.4 92.8 93.8 544.2 NC NC 71.3 54.2 47.4 386.8 NC NC
37 10–Undecenoic acid 112–38–9 NC S 118.2 67.4 60 600.2 NC NC 114.6 134 102.3 694.7 NC NC 96.7 93.8 101.6 582.2 NC NC
38 N,N–Dimethylbenzylamine 103–83–3 1BC L 97.4 50 20.6 168 1BC 1BC 98 38.5 19.7 156.2 1BC 1BC 85.9 44.1 14.9 144.9 1BC 1BC
39 Fluoboric acid 
(hydrogentetrafluoroborate) 
(48%)
16872–11–0 1BC L 11.5 4.1 3.5 11.5 1A 1A 18.9 4.1 4.8 18.9 1A 1A 9.6 2.5 2.7 9.6 1A 1A
40 Maleic anhydride 108–31–6 1BC S 78.8 13 2.7 91.8 1BC 1BC 72.5 10.1 4.3 82.6 1BC 1BC 80.2 6 5.5 86.2 1BC 1BC
41 60/40 octanoic/decanoc 
acid
68937–75–7 1BC L 77.4 7.4 2 84.8 1BC 1BC 55 12.4 3.4 67.4 1BC 1BC 103.6 18 7.3 121.6 1BC 1BC
42 55/45 octanoic/decanoc 
acid
68937–75–7 1BC L 59.3 18 4.1 77.3 1BC 1BC 68.8 13.6 4.6 82.4 1BC 1BC 103.2 7.6 3 110.8 1BC 1BC
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43 65/35 octanoic/decanoic 
acid
68937–75–7 1BC L 62.4 8.9 3.4 71.3 1BC 1BC 84.4 7.4 2.7 91.8 1BC 1BC 100.7 8.5 3.5 109.2 1BC 1BC
44 N,N-
dimethylisopropylamine
996–35–0 1BC L 94.3 12.9 8.9 107.2 1BC 1BC 87.7 14.2 8.3 101.9 1BC 1BC 77.6 13.7 9.4 91.3 1BC 1BC
45 Hydrochloric acid (14.4%) 7647–01–0 1BC L 69.3 5.7 1.9 75 1BC 1BC 63.3 2.2 4.6 65.5 1BC 1BC 65.3 2.5 6.8 67.8 1BC 1BC
46 n-Heptylamine 111–68–2 1BC L 36.2 50.7 31.9 118.8 1BC 1BC 43.9 25.5 9.7 69.4 1BC 1BC 26.2 22.9 13.3 26.2 1A 1A
47 Octanoic acid (caprylic acid) 124–07–2 1BC L 16.5 4.1 5.3 16.5 1A 1A 25 6.7 5.3 25 1A 1A 18.2 3.7 3.7 18.2 1A 1A
48 Carvacrol 499–75–2 1BC L 48.9 23.4 12.1 72.3 1BC 1BC 57.3 26.5 12.5 83.8 1BC 1BC 73.4 31.1 14.7 104.5 1BC 1BC
49 2-tert-Butylphenol 88–18–6 1BC L 86.3 7.5 12.3 93.8 1BC 1BC 52.9 20.8 9.2 73.7 1BC 1BC 60.7 7.2 9.7 67.9 1BC 1BC
50 Methacrolein 78–85–3 1BC L 85.4 20.6 0 106 1BC 1BC 122.3 32.6 45.4 154.9 1BC 1BC 92.3 42.9 27 162.2 1BC 1BC
51 Lactic acid 598–82–3 1BC L 80.2 9.4 6.8 89.6 1BC 1BC 72.3 6.3 4 78.6 1BC 1BC 93.6 8.9 4.2 102.5 1BC 1BC
52 Sodium bisulphate 
monohydrate
10034–88–5 1BC S 108 51.5 12.2 171.7 1BC 1BC 102.3 40.9 27.2 170.4 1BC 1BC 88.5 44.3 18.8 151.6 1BC 1BC
53 Glyoxylic acid monohydrate 563–96–2 1BC S 110.4 22.5 24.6 132.9 1BC 1BC 93.6 40.5 12.3 146.4 1BC 1BC 84.9 27.6 10.8 112.5 1BC 1BC
54 Sodium bisulphate 7681–38–1 1BC S 100.1 31.7 4 131.8 1BC 1BC 103.7 44.1 10.7 158.5 1BC 1BC 83.4 35.9 14.6 133.9 1BC 1BC
55 Cyclohexylamine 108–91–8 1BC L 89.8 13.1 8.4 102.9 1BC 1BC 46.8 3.4 18.3 50.2 1BC 1BC 73.9 9.2 10.3 83.1 1BC 1BC
56 2-Methylbutyric acid 600–07–7 1BC L 80.4 2.2 3.2 82.6 1BC 1BC 35.9 3.9 5.6 39.8 1BC 1A 83 5 3.6 88 1BC 1BC
57 Glycol bromoacetate (85%) 3785–34–0 1BC L 106.3 33.8 27 140.1 1BC 1BC 70.6 56 30.6 157.2 1BC 1BC 90.1 71.3 16.9 178.3 1BC 1BC
58 3-Methoxypropylamine 5332–73–0 1BC L 32.8 20.1 12.9 32.8 1A 1A 23.8 15.8 7.9 23.8 1A 1A 38 30 29.8 68 1BC 1BC
59 Allyl bromide 106–95–6 1BC L 113.9 37.9 8.2 160 1BC 1BC 119.4 17.4 21.9 136.8 1BC 1BC 108.7 21.1 7.7 129.8 1BC 1BC
60 1-(2-Aminoethyl)piperazine 140–31–8 1BC L 89.5 69.7 26.7 185.9 1BC 1BC 90.9 41.8 5.5 138.2 1BC 1BC 87.2 57.6 27.3 172.1 1BC 1BC
61 Iron(III) chloride 7705–08–0 1BC S 77.6 – 43.1 – NC – 80.4 58.6 50.6 430.8 NC NC 78 89.6 28.3 195.9 1BC 1BC
62 Phosphoric acid 7664–38–2 1BC L 65.6 20.6 1.7 86.2 1BC 1BC 113.1 9.8 2.3 122.9 1BC 1BC 67.4 20.8 9 88.2 1BC 1BC
63 Propionic acid 79–09–4 1BC L 3.2 2.5 3.9 3.2 1A 1A 5.5 11.8 4.3 5.5 1A 1A 5.8 4.3 9.3 5.8 1A 1A
64 Butyric acid 107–92–6 1BC L 3.8 2.4 6.3 3.8 1A 1A 8 2.8 3.4 8 1A 1A 14.8 4.7 4.6 14.8 1A 1A
65 Boron trifluoride -acetic acid 
complex
373–61–5 1BC L 29.1 4 5.9 29.1 1A 1A 71.6 3 2.3 74.6 1BC 1BC 28.9 4 3.1 28.9 1A 1A
66 Ethanolamine 141–43–5 1BC V 66.2 40.3 20.8 127.3 1BC 1BC 105.7 52.3 20.2 178.2 1BC 1BC 78.7 67.4 10.8 156.9 1BC 1BC
67 Hydrobromic acid (48%) 10035–10–6 1BC L 15.8 16.4 5.9 15.8 1A 1A 4.1 3.2 2.9 4.1 1A 1A 2.8 4.2 4.6 2.8 1A 1A
68 HCl + sulphuric acid + citric 
acid (5, 5, 5 wt.%)
– 1BC L 84.6 1.6 4.1 86.2 1BC 1BC 95.4 19.3 3.3 114.7 1BC 1BC 79.4 32.4 4.5 111.8 1BC 1BC
69 1,2-Diaminopropane 78–90–0 1A L 37.2 21.2 11.8 58.4 1BC 1BC 33 14.7 8.3 33 1A 1A 32 14.4 13 32 1A 1A
70 Phosphorus tribromide 7789–60–8 1A L 5.5 2.5 8.1 5.5 1A 1A 8.4 8 1.8 8.4 1A 1A 9.4 15.1 8.6 9.4 1A 1A
71 Boron trifluoride dihydrate 13319–75–0 1A L 2.4 4.2 2.7 2.4 1A 1A 2.5 2.6 1.9 2.5 1A 1A 4.5 2.9 2.6 4.5 1A 1A
(continued on next page)
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72 Acrylic acid 79–10–7 1A L 1.8 2.7 3.2 1.8 1A 1A 2.4 3.8 3.4 2.4 1A 1A 2.8 2.5 2.9 2.8 1A 1A
73 Formic acid 64–18–6 1A L 4.3 5.6 9.6 4.3 1A 1A 5.7 4.4 5.8 5.7 1A 1A 7.8 4.8 9.9 7.8 1A 1A
74 Dichloroacetyl chloride 79–36–7 1A L 5.6 6.3 8.3 5.6 1A 1A 5.8 8.5 10.2 5.8 1A 1A 6.2 10.5 8.1 6.2 1A 1A
75 Silver nitrate 7761–88–8 1A S 12.1 13.4 14.5 12.1 1A 1A 80.6 4.4 1.2 85 1BC 1BC 66.9 2.5 6.4 69.4 1BC 1BC
76 Phenol 108–95–2 1A S 29.8 21.8 23.1 29.8 1A 1A 22 18.4 18.5 22 1A 1A 21.4 17.2 17.2 21.4 1A 1A
77 Acetic acid 64–19–7 1A L 2.4 5.6 3 2.4 1A 1A 4.5 4.7 2.8 4.5 1A 1A 2.9 4.1 2.6 2.9 1A 1A
78 Bromoacetic acid 79–08–3 1A S 3 2.8 3.5 3 1A 1A 3 2.5 3.7 3 1A 1A 2 2.7 4.3 2 1A 1A
79 N,N–dimethyl–
dipropylenetriamine
10563–29–8 1A L 93.5 55.1 23.3 171.9 1BC 1BC 90.8 45 32 167.8 1BC 1BC 74.4 70.6 28.7 173.7 1BC 1BC
80 Sulphuric acid (98%) 7664–93–9 1A L 8 13.8 9.7 8 1A 1A 10.5 9.9 10.1 10.5 1A 1A 14.1 13.9 14.4 14.1 1A 1A
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Table 10
Contingency table for EpiSkin™ using current PM.
EpiSkin™ using its original PM, 240 predictions (80 chemicals tested 3 times
independently)
In vivo In vitro predictions
1A 1BC NC Total
1A 30 83.33% 6 16.67% 0 0.00% 36
1BC 20 21.51% 71 76.34% 2 2.15% 93
NC 0 0.00% 23 20.72% 88 79.28% 111
Total 50 100 90 240
Overall accuracy: 78.75%
Table 12
Contingency table for SkinEthic™ RHE using current PM.
SkinEthic™ RHE using its original PM, 240 predictions (80 chemicals tested 3 times
independently)
In vivo In vitro predictions
1A 1BC NC Total
1A 31 86.11% 5 13.89% 0 0.00% 36
1BC 43 46.24% 43 46.24% 7 7.52% 93
NC 3 2.70% 27 24.32% 81 72.97% 111
Total 77 75 88 240
Overall accuracy: 64.58%
2073B. Desprez et al. / Toxicology in Vitro 29 (2015) 2055–2080also shows that a majority of them fulﬁll this condition. This latter
explains why EpiSkin™ current PM presents a high rate (76.34%, see
Table 10) of correct predictions for Cat1BC (and low over-prediction
rate).
3.3. Results obtained on the basis of PMvar1
PMvar1 has been developed taking into consideration the observa-
tions on distribution of cell viability values. Therefore, as we observed
that all non-corrosive chemicals are above the cutoffs of v3 = 50% and
v60= 15% it seems logical to keep them under Step 1 of PMvar1 to dis-
criminate corrosive and non-corrosive chemicals. Then under Step 2 the
cutoff value of v3 is adjusted to allow the best discrimination possible
between Cat1A and Cat1BC. This approach is represented in Figs. 5, 6
and 7 and results are in Tables 14, 15 and 16.
PMvar1 has been tested for EpiDerm™, SkinEthic™ RHE and epiCS®.
Prediction rates are expressed over the total number of predictions
made. For each of these threemethods, the purposewas to improve pre-
dictions for Cat1BC, and the overall accuracy, and simultaneously to
keep the correct predictions for Cat1A at least at the same level of
EpiSkin™.
(1) For EpiDerm™, two cutoff values of x have been tested with
PMvar1, x = 20 or 25 (Table 14):
• With x = 20, the correct prediction rate of Cat1BC is 75.27%; the
correct prediction rate for Cat1A is 77.78% (below the target of
83.33%) and the overall accuracy is 75.00%.
• With x = 25, the correct prediction rate of Cat1BC is above 70%
(70.97%); the correct prediction rate for Cat1A reaches the target
value of 83.33% and the overall accuracy is 74.17%.
(2) For SkinEthic™ RHE, the two cutoff values that have been tested
with PMvar1 are x = 8 or 18 (Table 15):
• With x= 8, the correct prediction rate of Cat1BC is 68.82%; the cor-
rect prediction rate for Cat1A is 77.78% (below the target value of
83.33%) and the overall accuracy is 72.08%.
• With x = 18, the correct prediction rate of Cat1BC is above 61%
(61.29%); the correct prediction rate for Cat1A reaches the target
value of 83.33%.Table 11
Contingency table for EpiDerm™ using current PM.
EpiDerm™ using its original PM, 240 predictions (80 chemicals tested 3 times
independently)
In vivo In vitro predictions
1A 1BC NC Total
1A 33 91.67% 3 8.33% 0 0.00% 36
1BC 39 41.94% 54 58.06% 0 0.00% 93
NC 3 2.70% 26 23.42% 82 73.87% 111
Total 73 85 82 240
Overall accuracy: 70.41%(3) For epiCS®, the two cutoff values that have been tested with
PMvar1, x = 10 or 15 (Table 16):
• With x = 10, the correct prediction rate of Cat1BC is 65.57%; the
correct prediction rate for Cat1A is 79.17% (below the target value
of 83.33%) and the overall accuracy is 70.44%.
• With x = 15, the correct prediction rate of Cat1BC is 60.66%; the
correct prediction rate of Cat1A is 87.50% thus above the target
value of 83.33% and the overall accuracy is 69.81%.
Therefore for EpiDerm™, SkinEthic™ RHE and epiCS®, wewere able
to ﬁnd themost appropriated values of x (x=25; 18 and 15 respective-
ly) in PMvar1 that simultaneously increased the correct prediction rates
for Cat1BC and meet the target value of correct prediction rates for
Cat1A (see Section 2.2).
3.4. Results obtained on the basis of PMvar2
As for PMvar1, PMvar2 was also used for EpiDerm™, SkinEthic™
RHE and epiCS®, prediction rates are reported as well as the overall ac-
curacy. Figs. 8, 9 and 10 present the distribution of the composite indi-
cator vﬁn. Tables 17, 18 and 19 present the results for each test
method when several cutoff values of
(1) For EpiDerm™, two cutoff values have been tested y = 20 or 25
with z = 115 (Table 17)
• With y = 20, the correct prediction rate for Cat1BC is 75.27%; the
correct prediction rate for Cat1A is 77.78% (below the target of
83.33%) and the overall accuracy is 75.83%.
• With y = 25, the correct prediction rate of Cat1BC is slightly above
70%; the correct prediction rate for Cat1A is 83.33% and reaches the
target level of EpiSkin™ and the overall accuracy is 75.00%.
(2) For SkinEthic™ RHE, two cutoff values have been tested y = 11
or 18 with z = 130 (Table 18).
• With y = 11, the correct prediction rate of Cat1BC is 65.59%; the
correct prediction rate of Cat1A is 80.56% (below the target rate of
83.33%) and the overall accuracy is 71.25%.Table 13
Contingency table for epiCS® using current PM.
epiCS® using its original PM, 159 prediction (79 chemicals independently tested
twice plus 1 chemical tested once)
In vivo In vitro predictions
1A 1BC NC Total
1A 22 91.67% 2 8.33 0 0.00% 24
1BC 28 45.90 29 47.54% 4 6.56% 61
NC 0 0.00% 21 28.38 53 71.62% 74
Total 50 52 52 57 159
Overall accuracy: 65.41%
Fig. 1. Distribution of cell viability values in EpiDerm™ (dash line: 50% cutoff for v3; full
line: 15% cutoff for v60). Boxplots represent: median (line within box), 25th percentile
(lower hinge) and its lower adjacent value (lower adjacent line), 75th percentile (upper
hinge) and its upper adjacent value (upper adjacent line), outside values (dots).
Fig. 3. Distribution of cell viability values in epiCS (dash line: 50% cutoff for v3; full line:
15% cutoff for v60). Boxplots represent: median (line within box), 25th percentile
(lower hinge) and its lower adjacent value (lower adjacent line), 75th percentile (upper
hinge) and its upper adjacent value (upper adjacent line), outside values (dots).
2074 B. Desprez et al. / Toxicology in Vitro 29 (2015) 2055–2080• With y = 18, the correct prediction rate of Cat1BC is slightly above
61.29%; the correct prediction rate for Cat1A reaches the target level
of EpiSkin™ at 83.33% and the overall accuracy is 70.00%.
(3) For epiCS®, two cutoff values have been tested y = 7 or 18 with
z = 130 (Table 19)
• With y= 7, the correct prediction rate of Cat1BC is 68.85%; the cor-
rect prediction rate of Cat1A is 70.83% (below the target rate of
83.33% from EpiSkin™) and the overall accuracy is 70.44%.
• With y = 18, the correct prediction rate of Cat1BC is slightly below
60%; the correct prediction rate for Cat1A that reaches 91.67% is
over the target level of EpiSkin™ and the overall accuracy is 69.81%
When using PMvar2, the most appropriated values of y and z are
(x= 25, z = 115) for EpiDerm™ and (x= 18, z= 130) for SkinEthic™
RHE and epiCS®. These values, similarly to what has been done in
PMvar1, increased the correct prediction rates for Cat1BC and simulta-
neously allowed reaching the target value for Cat1A.Fig. 2. Distribution of cell viability values in SkinEthic™ RHE (dash line: 50% cutoff for v3;
full line: 15% cutoff for v60). Boxplots represent:median (linewithin box), 25th percentile
(lower hinge) and its lower adjacent value (lower adjacent line), 75th percentile (upper
hinge) and its upper adjacent value (upper adjacent line), outside values (dots).4. Discussion
4.1. Possible limitations
Results for EpiDerm™ and SkinEthic™ RHE are derived from 3 runs
while those for epiCS® are derived from 2 runs. Therefore there might
bemore uncertainty for results derived from epiCS®. However since re-
sults derived from epiCS® are consistent with those from the two other
methods and fall in the same range of values, they still could be consid-
ered as representative of the performance & changes observed regard-
ing this method.
Additionally, two other factors might inﬂuence the ﬁnal outcomes:
coloring and/or MTT-reducing chemicals, as they intrinsically have an
impact on OD. In 2012 and 2013 the OECD experts considered that
these factors did not inﬂuence the ﬁnal outcomes. Our investigation is
focused on predictionmodels only, and does not assess how predictions
could be inﬂuenced by physical–chemical properties e.g., coloring
chemicals and/or MTT-reducing chemicals, physical state, chemical
category. This can be performed using speciﬁc statistical modeling and
may be the subject of another paper. However it is noteworthy that,
as the set of chemicals used by all the RhE methods of this study is the
same, comparison can be done between methods when their PMs areFig. 4. Distribution of cell viability values in SkinEthic™ (dash line: 35% cutoff). Boxplots
represent: median (line within box), 25th percentile (lower hinge) and its lower adjacent
value (lower adjacent line), 75th percentile (upper hinge) and its upper adjacent value
(upper adjacent line), outside values (dots).
Fig. 5.Distribution of cell viabilities at 3 and 60min for EpiDerm™. Dash line: cut off of 50%
for v3 in original PM, dot line: cutoff of 15% for v60 in original PM and PMvar1, continuous
line: 25% cutoff in PMvar1 (x=25); long-dash line 20% cutoff in PMvar (x=20). Boxplots
represent: median (linewithin box), 25th percentile (lower hinge) and its lower adjacent
value (lower adjacent line), 75th percentile (upper hinge) and its upper adjacent value
(upper adjacent line), outside values (dots).
Fig. 7.Distribution of cell viabilities at 3 and 60min for epiCS®. Dash line: cut off of 50% for
v3 in original PM, dot line: cutoff of 15% for v60 in original PM and PMvar1, continuous
line: 15% cutoff in PMvar1 (x=15); long-dash line 10% cutoff in PMvar (x=10). Boxplots
represent: median (line within box), 25th percentile (lower hinge) and its lower adjacent
value (lower adjacent line), 75th percentile (upper hinge) and its upper adjacent value
(upper adjacent line), outside values (dots).
2075B. Desprez et al. / Toxicology in Vitro 29 (2015) 2055–2080changed, and therefore be able to assess the impact of these changes
both within a given method and between methods.
4.2. PMvar1 and PMvar2 both improved the predictions for Cat1BC and the
overall accuracy in comparison to the original PM
For Epiderm™, SkinEthic™ RHE and epiCS® both PMvar1 and
PMvar2 improved the predictions for Cat1BC and the overall accuracy
in comparison to the original predictionmodel. Simultaneously, the tar-
get value of correct prediction rates for Cat1A (i.e., 83.33%) was main-
tained in EpiDerm™ and SkinEthic™ RHE and surpassed in epiCS®.
This was obtained by selecting the most appropriated cutoff values of
x in PMvar1 and y & z in PMvar2. These results are summarized in
Table 20.
These results show that the extent of changes in predictionsmade by
PMvar1 and PMvar2 are comparable for the three tissuemodels.We can
conﬁrm this by using the kappa coefﬁcientwhen themost appropriated
values of x, y and z, for each testmethod (Sections 3.3 and 3.4), are used.Fig. 6.Distribution of cell viabilities at 3 and 60min for SkinEthic™ RHE. Dash line: cut off
of 50% for v3 in original PM, dot line: cutoff of 15% for v60 in original PM and PMvar1, con-
tinuous line: 18% cutoff in PMvar1 (x = 18); long-dash line 8% cutoff in PMvar (x = 8).
Boxplots represent: median (line within box), 25th percentile (lower hinge) and its
lower adjacent value (lower adjacent line), 75th percentile (upper hinge) and its upper
adjacent value (upper adjacent line), outside values (dots).This is presented in Table 21. It allows one to perform a quantitative
evaluation of the agreement between PMvar1 and PMvar2.
For Epiderm™, SkinEthic™ RHE and epiCS® the respective values of
agreement/kappa coefﬁcient are 99.17%/0.987, 100%/1.000 and 99.37%/
0.990 (Table 21). As all those values are close to 100% for the agreement
and 1.000 for the Kappa coefﬁcient, they support the fact that PMvar1
and PMvar2 provide comparable results as regards these 3 methods.
4.3. Speciﬁc advantages of PMvar2
4.3.1. PMvar2 additionally helps to perform ROC analysis
Brieﬂy, a ROC curve is a plotting graph where x-axis and y-axis are
respectively represented by (1-Speciﬁcity) and Sensitivity whenmono-
tonic variation of the cutoff value is applied for yes/no predictions
(Fawcett, 2006). The theoretical best performance is obtained when
(1-Speciﬁcity) value is 0 and simultaneously Sensitivity value is 1 and
therefore the area under ROC curve (AUROC) should be as close as pos-
sible to the value of 1 (Fawcett, 2006).
ROC curves are mostly obtained on the basis of a single variable
(however logistic regression modeling allow performing ROC analysis
on the basis of several dependent variables, see Section 2.2, sub-section
“Obtaining of ROC curves when PMvar2 is applied”), and thus prediction
models using different classiﬁcation variables—i.e., different cell
viabilities—cannot easily lead to obtaining ROC curves. The obtaining ofTable 14
Contingency table for EpiDerm™ using PMvar1.
EpiDerm™, PMvar1 x = 20 (not in italics) or 25 (in italics)
240 predictions (80 chemicals tested 3 times independently)
In vivo In vitro predictions
1A 1BC NC Total
1A 28 77.78% 8 22.22% 0 0.00% 36
30 83.33% 6 16.67% 0 0.00% 36
1BC 23 24.73% 70 75.27% 0 0.00% 93
27 29.03% 66 70.97% 0 0.00% 93
NC 2 1.80% 27 24.32% 82 73.87% 111
3 2.70% 26 23.42% 82 73.87% 111
Total 53 105 82 240
60 97 82 240
Overall accuracy:
75.00%
74.17%
Table 15
Contingency table for SkinEthic™ RHE using PMvar1.
SkinEthic™ RHE, PMvar1 x = 8 (not in italics) or 18 (in italics)
240 predictions (80 chemicals tested 3 times independently)
In vitro predictions
1A 1BC NC Total
28 77.78% 8 22.22% 0 0.00% 36
30 83.33% 6 16.67% 0 0.00% 36
22 23.66% 64 68.82% 7 7.53% 93
29 31.18% 57 61.29% 7 7.53% 93
0 0.00% 30 27.03% 81 72.97% 111
0 0.00% 30 27.03% 81 72.97% 111
50 102 88 240
59 93 88 240
Overall accuracy
72.08%
70.00%
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ready explained in Section 2.2 on data analysis. PMvar2 renders this
ROC analysis possible, which represents a signiﬁcant advantage in com-
parison to, for instance, the current PM.
Figs. 11, 12 and 13 display the ROC curves and areas under ROC
curves for the four test methods with regard to predictions: Cat1A ver-
sus (Cat1BC and Non-Corr.); Cat1BC versus (Cat1A and Non-Corr.) and
Non-Corr. versus (Cat1A and Cat1BC). The results of the ROC analysis
are the following:
(1) For predictions of Cat1A versus other categories (Fig. 11) the ROC
curves and the corresponding AUROCs are similar. The same con-
clusion is drawn for predictions Non-Corr. versus other categories
(Fig. 13). For prediction type ‘Cat1A versus other categories’, the
AUROCs are all close or above 0.90 i.e., respectively for EpiSkin™,
EpiDerm™, SkinEthic™ RHE, and epiCS®: 0.9277; 0.9326; 0.9130
and 0.8934.
• For predictions ‘Non-Corr. versus other categories’, the AUROCs
are all above 0.93 i.e., respectively for EpiSkin™, EpiDerm™,
SkinEthic™ RHE, and epiCS®: 0.9711; 0.9723; 0.9309 and 0.9434.
• Moreover a Chi-square test comparing the AUROCs presents a p-
value of 0.8785 for predictions ‘Cat1A versus other categories’ and
a p-value of 0.4552 for ‘Non-Corr. versus other categories’. Therefore
for these two types of predictions, the null hypothesis of similar per-
formance of the four methods cannot be excluded i.e., performances
are not signiﬁcantly different.
(2) For prediction ‘Cat1BC versus other categories’ (Fig. 12), the
AUROCs present contrasted values i.e., respectively for EpiSkin™,
EpiDerm™, SkinEthic™RHE, and epiCS®: 0.9177; 0.8035; 0.7044
and 0.6662. The Chi-square test comparing the AUROCs presentsTable 16
Contingency table for epiCS® using PMvar1.
epiCS®, PMvar1 x = 10 (not in italics) or 15 (in italics)
159 predictions (79 chemicals independently tested twice plus 1 chemical tested once)
In vitro predictions
1A 1BC NC Total
19 79.17% 5 20.83% 0 0.00% 24
21 87.50% 3 12.50% 0 0.00% 24
17 27.87% 40 65.57% 4 6.56% 61
20 32.79% 37 60.66% 4 6.56% 61
0 0.00% 21 28.38% 53 71.62% 74
0 0.00% 21 28.38% 53 71.62% 74
36 66 57 159
41 61 57 159
Overall accuracy:
70.44%
69.81%a p-value b 0.0001, the null hypothesis of equality of the four
areas is thus excluded. These areas are thus signiﬁcantly differ-
ent. This global result can be assessed further by pairwise com-
parison of the areas with Bonferroni correction. For all possible
pairs of areas, signiﬁcant differences are observed between
EpiSkin™ and SkinEthic™ RHE (p-value of 0.0013); EpiSkin™
and epiCS® (p-value of 0.0003). The p-value for comparison of
EpiSkin™ and EpiDerm™ is as the limit of the signiﬁcance, just
above the p-value of 0.05 for which the null hypothesis of iden-
tical AUROCS cannot be reject (p-value of 0.0565).
4.3.2. PMvar2 remains easily interpretable in the regulatory context
In both chemical and test method regulations, regulators focus on
the possible best regulatory use of the test methods according to their
performance and results that they provide, especially with regard to
human health protection. They have to address prediction models, and
those should therefore also be understandable and clear.
There are other possibilities to make predictions using simulta-
neously different values of cell viabilities (e.g., v3 and v60). One of
them is the logistic regression and that also allows ROC analysis
and thus ﬁnding the best possible cutoff. However, this type of anal-
ysis might not be working for all sub-categories. For example in the
case of EpiSkin™, when performing a logistic modeling (not shown)
for prediction of the sub-category Cat1BC, all dependent variables
v3, v60 and v240 return signiﬁcant coefﬁcients in the model. There-
fore it is not easy to determine which cell viability to consider for
changing the cutoff.
Furthermore, the interpretation of such logistic modeling may re-
main uneasy for regulators. They may face the challenge of developing
or amending regulation relying on mathematical models rather than
directly on threshold of cell viabilities. In contrast the use of the com-
posite cell indicator value used in PMvar2 may help getting round
these difﬁculties.
4.4. Revising TG 431 by inclusion of PMvar1 and/or 2: choosing the best
possible one
In Section 4.2 we showed that PMvar1 and PMvar2 performed
similarly. Therefore, the choice between these two PMs cannot be
based on their performance but rather on their speciﬁc advantages.
Usually the predictive performance of a test method is assessed by
examining contingency tables and predictions, but it is noteworthy
that those are obtained only for ﬁxed values of the cutoff chosen. In
contrast, the ROC analysis, which is enabled by PMvar2, has the
unique advantage to help understanding the predictive perfor-
mance for all possible cutoffs. PMvar2 may therefore represent a po-
tential additional tool offered to regulators, and although apparently
more complex it remains interpretable in the regulatory context
(Section 4.3.2). Nonetheless, PMvar2 is more likely to be used
for academic purposes or for advanced evaluation of the method
(e.g., during a peer review process of the test method). For instance,
when considering one tissue model, it is possible to compare the
areas under ROC curves between runs. In this comparison exercise,
the absence of statistically signiﬁcant difference would not provide
additional information (the null hypothesis of equal areas under
ROC cannot be rejected); while ﬁnding a signiﬁcant difference be-
tween runs would mean that, at least, one of them performs dif-
ferently from the two others and should trigger more investigation
(e.g., whether compliance with the protocol has been respected in
all runs). PMvar2 allows performing a more sophisticated statistical
analysis, which is a marked advantage.
PMvar1, in contrast to PMvar2, does not allow such advanced analy-
sis but may be easily understood by the regulators. Although the two-
step approach of PMvar1 might seem to be a complication, it might
Fig. 8.Distribution of composite cell viability indicator vﬁn for EpiDerm™ for PMvar2. Dot line: cutoff of vﬁn= 115 for vﬁn, continuous line: cutoff vﬁn= 25; long-dash line of vﬁn= 20.
Boxplots represent: median (linewithin box), 25th percentile (lower hinge) and its lower adjacent value (lower adjacent line), 75th percentile (upper hinge) and its upper adjacent value
(upper adjacent line), outside values (dots).
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that the inclusion of PMvar1 in TG 431 would require a less quantity of
work.
For regulatory purposes, we recommend that PMvar1 is used for
practical reasons. For academic or more advanced evaluation of the
test methods, we rather recommend that PMvar2 as it allows the
types of analysis presented above.Fig. 9.Distribution of composite cell viability indicator vﬁn for SkinEthic™ RHE for PMvar2. Dot lin
Boxplots represent:median (linewithinbox), 25thpercentile (lowerhinge) and its lower adjacent
adjacent line), outside values (dots).5. Conclusion
Reconstructed human Epidermis (RhE) test methods are playing a
prominent role in topical toxicology and for risk assessment purposes,
especially with regard to the development of Integrated Approaches
on Testing and Assessment (OECD, 2014a) and the ban of animal use
in cosmetic area in Europe since March 2013.e: cutoff of vﬁn=130 for vﬁn, continuous line: cutoff vﬁn=18; long-dash line of vﬁn=11.
value (lower adjacent line), 75thpercentile (upper hinge) and its upper adjacent value (upper
Fig. 10. Distribution of composite cell viability indicator vﬁn for ePiCS® for PMvar2. Dot line: cutoff of vﬁn = 130 for vﬁn, continuous line: cutoff vﬁn = 18; long-dash line of vﬁn = 7.
Boxplots represent: median (line within box), 25th percentile (lower hinge) and its lower adjacent value (lower adjacent line), 75th percentile (upper hinge) and its upper adjacent
value (upper adjacent line), outside values (dots).
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thesemethods shall be sufﬁciently protective in terms of human health,
i.e., shall at least be able to discriminate corrosive chemicals from non-
corrosive ones. Additionally, for industrial purposes and cost consid-
erations, especially with regard to the transport of chemicals, dis-
crimination within corrosive chemicals into sub-categories required in
regulation is of importance as well, providing prediction types Category
1A versus Category 1BC versus non-corrosive, on the basis of UN GHS
categories.
The last version of OECDTest GuidelineNo. 431 allows these types of
sub-categorization for four methods, EpiDerm™; EpiSkin™ and
SkinEthic™ RHE, and epiCS®. However the prediction models included
in this TG for EpiDerm™, SkinEthic™ RHE and epiCS® result in quite
high over-prediction rates of Cat1BC chemicals that are over-predicted
as Category 1A, while they present high correct predictions rates of Cat-
egory 1A and non-corrosive chemicals. For EpiSkin™, predictions pro-
vided can be used straightaway, in contrast to the three other methods.Table 17
Contingency table for EpiDerm™ using PMvar2.
EpiDerm™, PMvar2 y = 20 (not in italics) or 25 (in italics) and z = 115
240 predictions (80 chemicals tested 3 times independently)
In vivo In vitro predictions
1A 1BC NC Total
1A 28 77.78% 8 22.22% 0 0.00% 36
30 83.33% 6 16.67% 0 0.00% 36
1BC 23 24.73% 70 75.27% 0 0.00% 93
27 29.03% 66 70.97% 0 0.00% 93
NC 2 1.80% 25 22.52% 84 75.66% 111
3 2.70% 24 21.62% 84 75.66% 111
Total 53 103 84 240
60 96 84 240
Overall accuracy:
75.83%
75.00%Our analysis shows that the cutoff value of 50% cell viability at 3min
used in EpiDerm™, SkinEthic™ RHE and epiCS® to discriminate be-
tween Cat1A and Cat1BC is the main factor in causing this high over-
prediction rate. Switching from the original PM to the novel PMs
(PMvar1 or PMvar2) allow to obtain higher correct predictions for
Cat1BC in a range of 60–70%. Correct predictions for 1A are slightly
decreased, in parallel, but remain at least at the level of the
EpiSkin™ SCT. This slight decrease occurs in a much lower extent
than the increase of correct predictions for 1BC. Additionally, the
overall accuracy is also increased, for EpiDerm™ from around 70%
initially to around 75%, for SkinEthic™ RHE and epiCS® from around
65% initially to around 70%.
The composite indicator, vﬁn, used in PMvar2 presents the advan-
tages (i) to be easier to use, (ii) allow ROC analysis, since this analysis
was not straightaway forward with the original PM or PMvar1 and
(iii) remains accessible to regulators compared to the logistic modeling
which is a complex approach.Table 18
Contingency table for SkinEthic™ RHE using PMvar2.
SkinEthic™ RHE, PMvar2 y = 11 (not in italics) or 18 (in italics) and z = 130
240 predictions (80 chemicals tested 3 times independently)
In vitro predictions
1A 1BC NC Total
29 80.56% 7 19.44% 0 0.00% 36
30 83.33% 6 16.67% 0 0.00% 36
25 26.88% 61 65.59% 7 7.53% 93
29 31.18% 57 61.29% 7 7.53% 93
0 0.00% 30 27.03% 81 72.97% 111
0 0.00% 30 27.03% 81 72.97% 111
54 98 88 240
59 93 88 240
Overall accuracy
71.25%
70.00%
Table 19
Contingency table for epiCS® using PMvar2.
epiCS®, PMvar2 y = 7 (not in italics) or 18 (in italics) and z = 130
159 predictions (79 chemicals independently tested twice plus 1 chemical tested once)
In vitro predictions Total
1A 1BC NC
17 79.17% 7 29.17% 0 0.00% 24
22 91.67% 2 8.33% 0 0.00% 24
14 27.87% 42 68.85% 5 8.20% 61
20 32.79% 36 59.02% 5 8.20% 61
0 0.00% 21 28.38% 53 71.62% 74
0 0.00% 21 28.38% 53 71.62% 74
31 70 58 159
42 59 58 159
Overall accuracy:
70.44%
69.81%
Table 20
Variations of correct predictions observed in comparison to the original predictionmodel.
The numbers represents the difference of correct prediction rates, for each sub-category,
between PMvar1 or PMvar2 and the original prediction model.
Tissue model Sub-category
considered
PMvar1 with cutoff
value of
PMvar2 with cutoff
value of
EpiDerm™ x = 25 y = 25, z = 115
Cat1BC +12.91% +12.91%
Cat1A −8.34% −8.34%
Overall accuracy +4.59% +4.59%
SkinEthic™ RHE x = 18 y = 18, z = 130
Cat1BC +15.05% +12.78%
Cat1A −2.78% −2.78%
Overall accuracy +5.42% +5.42%
epiCS® x = 15 y = 18, z = 130
Cat1BC +13.12% +11.48%
Cat1A −4.17% 0.00%
Overall accuracy +4.40% +4.40%
Fig. 11. ROC curves and areas under ROC for prediction Cat1A versus (combined) other
categories.
Fig. 12. ROC curves and areas under ROC for prediction Cat1BC versus (combined) other
categories.
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sis performed was consistent with their abilities to sub-categorize
chemicals as they appear in their respective 3 × 3 contingency tables
(when using PMvar2). EpiDerm™, SkinEthic™ RHE and epiCS® ROC
curves are consistent with their good abilities for identifying Cat1A
and non-corrosive chemicals and increased ability to identify Cat1BC;
while EpiSkin™ ROC curves are consistent with its good abilities for
identifying Cat1A, and non-corrosive chemicals, as well as greater abil-
ities to identify Cat1BC chemicals.
Overall, for EpiDerm™, SkinEthic™ RHE and epiCS® prediction
models regarding sub-categorization of corrosive can be signiﬁcantly
improved by changing of PM. These results show the key role played
by PMs of RhE methods for skin corrosion endpoint, and support the
fact that they should be carefully adapted for the intended regulatory
use. It ultimately supports the need for a possible revision of OECD TG
431 with regard to sub-categorization of chemicals performed by
these three methods. PMvar2 has the unique advantage to enable ROCTable 21
Agreement and Kappa coefﬁcient between PMvar1 and PMvar2 for each test method.
EpiDerm™ SkinEthic™ RHE
PMvar2 PMvar2
Cat1A Cat1BC NC Total Cat1A
PMvar1 Cat1A 60 0 0 56 PMvar1 Cat1A 59
Cat1BC 0 96 2 102 Cat1BC 0
NC 0 0 82 82 NC 0
Total 60 96 84 240 Total 59
Agreement: 99.17%
Kappa: 0.987
Agreement 100.00%
Kappa: 1.00analysis and to permit advanced statistics and easier comparison of
the predictive capacities of the methods. Although we showed that
PMvar1 and PMvar2 have similar performances and provide compara-
ble predictions, in the regulatory contextwe think that PMvar1 is easier
to use and be understood. Therefore it is our opinion that PMvar1
should be implemented in TG 431.Conﬂict of interest statement
The authors declare no conﬂicts of interest.epiCS®
PMvar2
Cat1BC NC Total Cat1A Cat1BC NC Total
0 0 59 PMvar1 Cat1A 41 0 0 41
93 0 93 Cat1BC 0 60 0 60
0 88 88 NC 0 1 57 58
93 88 240 Total 41 61 57 159
Agreement: 99.37%
Kappa: 0.990
Fig. 13.ROC curves and areas under ROC for predictionNon-Corr. versus (combined) other
categories.
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